<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease - Saglimbene, VM - 2017 | Cochrane Library</title> <meta content="Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease - Saglimbene, VM - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009904.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease - Saglimbene, VM - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009904.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009904.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease" name="citation_title"/> <meta content="Valeria M Saglimbene" name="citation_author"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Marinella Ruospo" name="citation_author"/> <meta content="Diaverum" name="citation_author_institution"/> <meta content="Patrizia Natale" name="citation_author"/> <meta content="Diaverum" name="citation_author_institution"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="giovanni.strippoli@uniba.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD009904.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009904.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009904.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009904.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia [blood, *drug therapy, etiology]; Cardiovascular Diseases [etiology]; Cause of Death; Darbepoetin alfa [adverse effects, therapeutic use]; Epoetin Alfa [adverse effects, therapeutic use]; Erythrocyte Transfusion [adverse effects, statistics &amp; numerical data]; Erythropoietin [adverse effects, *therapeutic use]; Hypertension [etiology]; Polyethylene Glycols [adverse effects, *therapeutic use]; Publication Bias; Randomized Controlled Trials as Topic; Recombinant Proteins [adverse effects, therapeutic use]; Renal Dialysis; Renal Insufficiency, Chronic [*complications, therapy]; Thrombosis [etiology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009904.pub2&amp;doi=10.1002/14651858.CD009904.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009904\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009904\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009904.pub2",title:"Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease",firstPublishedDate:"Aug 7, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009904.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009904.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009904.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009904.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009904.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009904.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009904.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009904.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009904.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009904.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2968 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009904.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/appendices#CD009904-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/table_n/CD009904StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/table_n/CD009904StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#CD009904-cr-0002">Valeria M Saglimbene</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#CD009904-cr-0003">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#CD009904-cr-0004">Marinella Ruospo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#CD009904-cr-0005">Patrizia Natale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#CD009904-cr-0006">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information#CD009904-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information/en#CD009904-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009904.pub2">https://doi.org/10.1002/14651858.CD009904.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009904-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009904-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009904-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009904-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009904-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009904-abs-0001" lang="en"> <section id="CD009904-sec-0001"> <h3 class="title" id="CD009904-sec-0001">Background</h3> <p>Continuous erythropoiesis receptor activator (CERA) is a newer, longer acting ESA which might be preferred to other ESAs (epoetin or darbepoetin) based on its lower frequency of administration. Different dosing requirements and molecular characteristics of CERA compared with other ESAs may lead to different health outcomes (mortality, cardiovascular events, quality of life) in people with anaemia and chronic kidney disease (CKD). </p> </section> <section id="CD009904-sec-0002"> <h3 class="title" id="CD009904-sec-0002">Objectives</h3> <p>To assess benefits and harms of CERA compared with other epoetins (darbepoetin alfa and epoetin alfa or beta) or placebo/no treatment or CERA with differing strategy of administration for anaemia in individuals with CKD. </p> </section> <section id="CD009904-sec-0003"> <h3 class="title" id="CD009904-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Specialised Register to 13 June 2017 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD009904-sec-0004"> <h3 class="title" id="CD009904-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of at least three months' duration, comparing CERA with a different ESA (darbepoetin alfa or epoetin alfa or beta) or placebo or standard care or versus CERA with different strategies for administration in people with any stage of CKD. </p> </section> <section id="CD009904-sec-0005"> <h3 class="title" id="CD009904-sec-0005">Data collection and analysis</h3> <p>Data were extracted by two independent investigators. We summarised patient‐centred outcomes (all‐cause and cardiovascular mortality, major adverse cardiovascular events, red cell blood transfusion, iron therapy, cancer, hypertension, seizures, dialysis vascular access thrombosis, drug injection‐related events, hyperkalaemia and health‐related quality of life and haemoglobin levels) using random effects meta‐analysis. Treatment estimates were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes and mean differences or standardized mean difference with 95% CI for continuous outcomes. </p> </section> <section id="CD009904-sec-0006"> <h3 class="title" id="CD009904-sec-0006">Main results</h3> <p>We included 27 studies involving 5410 adults with CKD. Seven studies (1273 participants) involved people not requiring dialysis, 19 studies (4209 participants) involved people treated with dialysis and one study (71 participants) evaluated treatment in recipients of a kidney transplant. Treatment was given for 24 weeks on average. No data were available for children with CKD. Studies were generally at high or unclear risk of bias from allocation concealment and blinding of outcomes. Only two studies masked participants and investigators to treatment allocation. One study compared CERA with placebo, nine studies CERA with epoetin alfa or beta, nine studies CERA with darbepoetin alfa, and two studies compared CERA with epoetin alfa or beta and darbepoetin alfa. Three studies assessed the effects of differing frequencies of CERA administration and five assessed differing CERA doses. </p> <p>There was low certainty evidence that CERA had little or no effects on mortality (RR 1.07, 95% CI 0.73 to 1.57; RR 1.11, 95% CI 0.75 to 1.65), major adverse cardiovascular events (RR 5.09, 95% CI 0.25 to 105.23; RR 5.56, 95% CI 0.99 to 31.30), hypertension (RR 1.01, 95% CI 0.75 to 1.37; RR 1.00, 95% CI 0.79 to 1.28), need for blood transfusion (RR 1.02, 95% CI 0.72 to 1.46; RR 0.94, 95% CI 0.55 to 1.61), or additional iron therapy (RR 1.03, 95% CI 0.91 to 1.15; RR 0.99, 95% CI 0.95 to 1.03) compared to epoetin alfa/beta or darbepoetin alfa respectively. There was insufficient evidence to compare the effect of CERA to placebo on clinical outcomes. Only one low quality study reported that CERA compared to placebo might lead to little or no difference in the risk of major cardiovascular events (RR 2.97, 95% CI 0.31 to 28.18) and hypertension ((RR 0.73, 95% CI 0.35 to 1.52). There was low certainty evidence that different doses (higher versus lower) or frequency (twice versus once monthly) of CERA administration had little or no different effect on all‐cause mortality (RR 3.95, 95% CI 0.17 to 91.61; RR 0.97, 95% CI 0.56 to 1.66), hypertension (RR 0.45, 95% CI 0.08 to 2.52; RR 0.85, 95% CI 0.60 to 1.21), and blood cell transfusions (RR 4.16, 95% CI 0.89 to 19.53; RR 0.91, 95% CI 0.51 to 1.62). No studies reported comparative treatment effects of different ESAs on health‐related quality of life. </p> </section> <section id="CD009904-sec-0007"> <h3 class="title" id="CD009904-sec-0007">Authors' conclusions</h3> <p>There is low certainty evidence that CERA has little or no effects on patient‐centred outcomes compared with placebo, epoetin alfa or beta or darbepoetin alfa for adults with CKD. The effects of CERA among children who have CKD have not studied in RCTs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009904-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009904-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009904-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009904-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009904-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009904-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009904-abs-0003" lang="en"> <h3>CERA treatment for anaemia in people with chronic kidney disease</h3> <p><b>What is the issue?</b> </p> <p>Several treatments are available to treat anaemia in people who have kidney disease. These treatments boost the body's ability to produce red blood cells that take oxygen from the lungs and carry oxygen around the body. The kidney normally releases this hormone that prevents anaemia, but when the kidney function is low this hormone is insufficient to maintain an optimal level of red blood cells. </p> <p>Several synthetic versions of this hormone (called erythropoietin) are used as drugs that can be given into the skin or the directly blood stream and can completely correct anaemia from kidney disease. Several different treatment versions of erythropoietin are available in some parts of the world ‐ these treatments generally differ by how often they need to be given to have an effect. The oldest versions of the drug (epoetin) need to be given several times per week, whereas newer drugs (darbepoetin and CERA) can be given much less often. </p> <p>Unfortunately, when high doses of anaemia treatments are used to achieve high haemoglobin levels, they can increase the risks of complications like a heart attack or stroke. Because of this risk, people are advised to use the dose of anaemia treatment that gives relief from the problems of anaemia (tiredness, breathlessness) but to avoid higher doses that may cause problems. However, it is not certain whether the different versions of the anaemia drugs have different risks of complications. </p> <p><b>What did we do?</b> </p> <p>This review looked at whether CERA has different complication rates and benefits from correcting anaemia (improved quality of life) than other anaemia treatments. </p> <p><b>What did we find?</b> </p> <p>We found 27 studies involving over 5410 people with kidney disease that looked at the benefits and complications of different anaemia treatments, comparing the newer anaemia treatment (CERA) with the older treatments (darbepoetin and epoetin alfa or beta). We found that it was uncertain whether anaemia drugs had different effects on heart disease complications, life expectancy, or anaemia in the people receiving treatment to increase their blood count. There was no information about whether CERA led to better quality of life for people receiving this drug. </p> <p><b>Conclusions</b> </p> <p>Based on the information in this Cochrane review, clinical decisions about the choice of different anaemia drugs can be based on drug cost and availability. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009904-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009904-sec-0090"></div> <h3 class="title" id="CD009904-sec-0091">Implications for practice</h3> <section id="CD009904-sec-0091"> <p>Currently, there is no high quality evidence that CERA for treatment of anaemia in adults with CKD has different effects on mortality and other patient‐level outcomes. It is also unclear whether different ESAs have different efficacy for health‐related quality of life. Given the inconclusive effects of CERA on quality of life, cardiovascular events and survival, clinical decisions about the choice of ESA might be based on drug cost and availability. </p> </section> <h3 class="title" id="CD009904-sec-0092">Implications for research</h3> <section id="CD009904-sec-0092"> <p>While this review highlights an important evidence gap in the comparative effects of different ESAs in adults and children with CKD, particularly for patient‐level outcomes including quality of life, further additional studies are unlikely to be a priority for funders or drug manufacturers and RCTs continue to under‐report harms (<a href="./references#CD009904-bbs2-0056" title="PitrouI , BoutronI , AhmadN , RavaudP . Reporting of safety results in published reports of randomized controlled trials. Archives of Internal Medicine2009;169(19):1756‐61. [MEDLINE: 19858432] ">Pitrou 2009</a>). Ongoing comparative analysis of large non‐randomised data sets has recently been carried out comparing epoetin with darbepoetin alfa (<a href="./references#CD009904-bbs2-0070" title="WinkelmayerWC , ChangTI , MitaniAA , Wilhelm‐LeenER , DingV , ChertowGM , et al. Longer‐term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi‐experimental cohort study. American Journal of Kidney Diseases2015;66(1):106‐13. [MEDLINE: 25943715] ">Winkelmayer 2015</a>) that may offer an important tool to address uncertainties about drug adverse effects for different ESAs, particularly CERA) and could include longer term data than available in current RCTs. In addition, the consensus process that will identify core clinical outcomes for reporting in all nephrology studies will help ensure that future studies identify benefits and harms of treatments that are most relevant to patients, clinicians and other stakeholders (<a href="./references#CD009904-bbs2-0066" title="TongA , MannsB , HemmelgarnB , WheelerDC , TugwellP , WinkelmayerWC , et al. Standardised outcomes in nephrology ‐ Haemodialysis (SONG‐HD): study protocol for establishing a core outcome set in haemodialysis. Trials [Electronic Resource]2015;16:364. [MEDLINE: 26285819] ">Tong 2015</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009904-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009904-sec-0022"></div> <div class="table" id="CD009904-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CERA for the anaemia of CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> CKD patients (any stage) treated for anaemia </p> <p><b>Intervention:</b> CERA </p> <p><b>Comparison:</b> epoetin alfa or beta, darbepoetin alfa, differing strategies for administration (higher versus lower doses; longer versus shorter dosing intervals) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b> Comparison</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> <p><b>per 100 patients treated for 12 months</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments<sup>#</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more (2 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.73 to 1.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1846 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more (2 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.75 to 1.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1657 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA Q2W</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more (3 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.56 to 1.66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA lower dose</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.95 (0.17 to 91.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>One or more red cell transfusions</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (3 fewer to 5 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.72 to 1.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1824 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer<br/> (5 fewer to 7 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.55 to 1.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1728 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> <p>Inconsistency ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA Q2W</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer<br/> (5 fewer to 7 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.51 to 1.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA lower dose</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 more<br/> (3 fewer to 519 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.16 (0.89 to 19.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> <p>Inconsistency ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vascular access thrombosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more (6 fewer to 15 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (0.49 to 2.40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1419 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> <p>Inconsistency ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA Q2W</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer (4 fewer to 4 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.61 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA lower dose</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more (5 fewer to 7 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.75 to 1.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1821 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more (4 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.79 to 1.28)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1752 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA Q2W</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer (5 fewer to 3 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.60 to 1.21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA lower dose</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 fewer (50 fewer to 82 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45 (0.08 to 2.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>PLACEBO</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 fewer (4 fewer to 4 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.37 to 1.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>235 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; Q2W<b>:</b> once every 2 weeks administration; Q4W<b>:</b> once every 4 weeks administration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><sup>#</sup>We did not downgrade for reason of publication bias as insufficient studies contributed to treatment estimates to draw meaningful conclusions </p> <p>GRADE Working Group grades of evidence</p> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CERA ‐ continuous erythropoiesis receptor activator</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009904-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009904-sec-0023"></div> <section id="CD009904-sec-0024"> <h3 class="title" id="CD009904-sec-0024">Description of the condition</h3> <p>Anaemia is a common occurrence in people with chronic kidney disease (CKD) (<a href="./references#CD009904-bbs2-0045" title="HsuCY , McCullochCE , CurhanGC . Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. Journal of the American Society of Nephrology2002;13(2):504‐10. [MEDLINE: 11805181] ">Hsu 2002</a>). Because erythropoietin is synthesised predominantly by the normal kidney, CKD leads to insufficient erythropoietin release that impairs red blood cell production. Before recombinant human epoetins were introduced, people with end‐stage kidney disease (ESKD) frequently experienced profound anaemia and were dependent on iron replacement therapy and repeated red blood cell transfusions. In observational studies, lower haemoglobin levels have been consistently associated with cardiac abnormalities, mortality and cardiovascular events in people with ESKD (<a href="./references#CD009904-bbs2-0039" title="FoleyRN , ParfreyPS , HarnettJD , KentGM , MurrayDC , BarrePE . The impact of anemia on cardiomyopathy, morbidity and mortality in end‐stage renal disease. American Journal of Kidney Diseases1996; Vol. 28, issue 1:53‐61. [MEDLINE: 8712222] ">Foley 1996</a>; <a href="./references#CD009904-bbs2-0050" title="LacsonEJr , QangW , HakinRM , TengM , LazarusJM . Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. American Journal of Kidney Diseases2009; Vol. 53, issue 1:79‐90. [MEDLINE: 18930570] ">Lacson 2009</a>; <a href="./references#CD009904-bbs2-0057" title="RobertsTL , FoleyRN , WeinhandlED , GilbertsonDT , CollinsAJ . Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrology Dialysis Transplantation2006;21(6):1652‐62. [MEDLINE: 16449283] ">Roberts 2006</a>; <a href="./references#CD009904-bbs2-0058" title="RobinsonBM , JoffeMM , BernsJS , PisoniRL , PortFK , FeldmanHI . Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time.[Erratum in Kidney Int. 2005 Dec;68(6):2934]. Kidney International2005;68(5):2323‐30. [MEDLINE: 16221236] ">Robinson 2005</a>) and the risk of ESKD in those not yet requiring dialysis (<a href="./references#CD009904-bbs2-0049" title="KovesdyCP , TrivediBK , Kalantar‐ZadehK , AndersonJE . Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney International2006; Vol. 69, issue 3:560‐4. [MEDLINE: 16395253] ">Kovesdy 2006</a>). However in subsequent randomised controlled trials (RCTs), human recombinant epoetins (erythropoietin or darbepoetin) corrected anaemia and reduced red cell transfusions in people with CKD, but targeting higher haemoglobin levels with these drugs increased mortality and cardiovascular events, without clinical improvements in quality of life (<a href="./references#CD009904-bbs2-0035" title="BesarabA , BoltonWK , BrowneJK , EgrieJC , NissensonAR , OkamotoDM , et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine1998;339(9):584‐90. [MEDLINE: 9718377] ">Besarab 1998</a>; <a href="./references#CD009904-bbs2-0037" title="DruekeTB , LocatelliF , ClyneN , EckardtKU , MacdougallIC , TsakirisD , et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine2006;355(20):2071‐84. [MEDLINE: 17108342] ">Drueke 2006</a>; <a href="./references#CD009904-bbs2-0063" title="SinghAK , SzczechL , TangKL , BarnhartH , SappS , WolfsonM , et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine2006;355(20):2085‐98. [MEDLINE: 17108343] ">Singh 2006</a>; <a href="./references#CD009904-bbs2-0067" title="PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] ">TREAT Study 2009</a>). The mechanisms by which epoetins increase cardiovascular events remains unclear; it is possible that the epoetin dose or action rather than targeted haemoglobin level may account for the adverse effects associated with these drugs. Patients who have lower responsiveness to epoetin treatment and require higher treatment doses have increased rates of mortality (<a href="./references#CD009904-bbs2-0048" title="KilpatrickRD , CritchlowCW , FishbaneS , BesarabA , Stehman‐BreenC , KrishnanM , et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1077‐83. [MEDLINE: 18417744] ">Kilpatrick 2008</a>; <a href="./references#CD009904-bbs2-0064" title="SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ">Solomon 2010</a>). Novel treatment strategies for the anaemia of CKD are now needed to minimise transfusion dependence and improve quality of life and survival without incurring epoetin‐related harms. </p> </section> <section id="CD009904-sec-0025"> <h3 class="title" id="CD009904-sec-0025">Description of the intervention</h3> <p>Human recombinant epoetins were first used to treat anaemia in CKD over 30 years ago (<a href="./references#CD009904-bbs2-0069" title="WinearlsCG , OliverDO , PippardMJ , ReidC , DowningMR , CotesPM . Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet1986;2(8517):1175‐8. [MEDLINE: 2877323] ">Winearls 1986</a>). This class of drug includes erythropoietin (alfa and beta), darbepoetin alfa, and methoxy ethylene‐glycol erythropoietin beta (also known as continuous erythropoietin receptor activator, CERA). Recombinant human erythropoietin alfa and beta are almost identical to endogenous erythropoietin hormone in the sequence of amino acids, but each differs in their glycosylation pattern (the attachment of carbohydrates to the erythropoietin protein). Erythropoietin alfa and beta have short circulating half‐lives (6 to 24 hours after intravenous (IV) or subcutaneous (SC) injection respectively) and are administered two or three times weekly to maintain haemoglobin levels (<a href="./references#CD009904-bbs2-0041" title="HalstensonCE , MacresM , KatzSA , SchniedersJR , WatanabeM , SobotaJT , et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology &amp; Therapeutics1991;50(6):702‐12. [MEDLINE: 1752115] ">Halstenson 1991</a>; <a href="./references#CD009904-bbs2-0059" title="SalmonsonT , DanielsonBG , WikströmB . The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. British Journal of Clinical Pharmacology1990;26(6):709‐13. [MEDLINE: 2378790] ">Salmonson 1990</a>). Darbepoetin alfa, a more recently developed epoetin, is more highly glycosylated and has a longer half‐life (24 to 72 hours after IV or SC injection respectively), allowing a dosing interval of once a week to once every other week (<a href="./references#CD009904-bbs2-0052" title="MacdougallIC , PadhiD , JangG . Pharmacology of darbepoetin alfa. Nephrology Dialysis Transplantation2007;22 Suppl 4:iv2‐iv9. [MEDLINE: 17526547] ">Macdougall 2007</a>; <a href="./references#CD009904-bbs2-0053" title="PadhiD , NiL , CookeB , MarinoR , JangG . An extended terminal half‐life for darbepoetin alfa: results from a single‐dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clinical Pharmacokinetics2006;45(5):503‐10. [MEDLINE: 16640455] ">Padhi 2006</a>). CERA is a pegylated epoetin with a comparable half‐life of about 130 hours when administered either IV or SC extending dosing intervals further to once every two to four weeks (<a href="./references#CD009904-bbs2-0028" title="MacdougallIC , ReignerB , DoughertyFC . Consistent pharmacokinetic properties of CERA (Continuous Erythropoietin Receptor Activator) in healthy volunteers and in patients with CKD) [abstract no: 89]. American Journal of Kidney Diseases2006;47(4):A41. [CENTRAL: CN‐00583919] MacdougallIC , RobsonR , OpatrnaS , LiogierX , PannierA , JordanP , et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1211‐5. [MEDLINE: 17699350] MacdougallIC , RobsonR , OpatrnaS , LiogierX , PannierA , ReignerB , et al. Pharmacologic profile of CERA (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients (pts) following intravenous (IV) and subcutaneous (SC) administration [abstract no: SA‐PO926]. Journal of the American Society of Nephrology2005;16:759A. [CENTRAL: CN‐00795029] ">Macdougall 2006</a>). Glycosylation and pegylation account for the longer half‐life of these molecules and also a lower affinity for the erythropoietin receptors, both factors resulting in a prolonged stimulation of the receptors and allowing a longer dosing interval administration (<a href="./references#CD009904-bbs2-0038" title="EgrieJC , BrowneJK . Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer2001;84 Suppl 1:3‐10. [MEDLINE: 11308268] ">Egrie 2001</a>; <a href="./references#CD009904-bbs2-0046" title="JarschM , KubbiesM , LanzendorferM , HaselbeckA , BrandtM . CERA acts differently at the erythropoietin (EPO) receptor compared with epoetin beta: UT‐7 and CD34+ cell stimulation assays [abstract no. SA‐PO209]. 39th Annual Meeting and Scientific Exhibition of the American Society of Nephrology; Renal Week: 2006 Nov 14‐19; San Diego (CA). 2006. ">Jarsch 2006</a>; <a href="./references#CD009904-bbs2-0062" title="SinclairAM . Erythropoiesis stimulating agents: approaches to modulate activity. Biologics2013;7:161‐74. [MEDLINE: 23847411] ">Sinclair 2013</a>). </p> </section> <section id="CD009904-sec-0026"> <h3 class="title" id="CD009904-sec-0026">How the intervention might work</h3> <p>Extending dosing intervals using CERA in place of erythropoietin and darbepoetin has the potential to provide more convenient treatment, lower costs of care, and more stable haemoglobin levels within a narrow target range. Different dosing requirements and molecular characteristics of CERA may also lead to different health outcomes (mortality, cardiovascular events, quality of life) compared with erythropoietin and darbepoetin in people with anaemia and CKD, independent of achieved haemoglobin levels. </p> </section> <section id="CD009904-sec-0027"> <h3 class="title" id="CD009904-sec-0027">Why it is important to do this review</h3> <p>Anaemia is common among people with CKD and is associated with worse outcomes. Considerable debate and controversy surround the optimal management of the anaemia of CKD. So far, and against early predictions, erythropoietin and darbepoetin alfa used targeting higher haemoglobin levels, increased cardiovascular events in this population. RCTs of CERA are now available and require systematic evaluation to determine the evidence for efficacy and safety of CERA in CKD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009904-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009904-sec-0028"></div> <p>This review aimed to look at the benefits and harms of CERA compared with other epoetins (darbepoetin alfa and erythropoietin alfa or beta) or placebo/no treatment or CERA with differing strategy of administration for anaemia in individuals with CKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009904-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009904-sec-0029"></div> <section id="CD009904-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009904-sec-0031"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at CERA alone or in combination with other non‐randomised co‐interventions (such as iron supplementation or red cell transfusion) in people with CKD (any stage) and anaemia were included. The first period of randomised cross‐over studies was also considered. Studies were considered without language restriction. Studies of at least three months' follow‐up duration were included. </p> </section> <section id="CD009904-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD009904-sec-0033"> <h5 class="title">Inclusion criteria</h5> <p>Studies included people with CKD (as defined by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF/KDOQI) guidelines (<a href="./references#CD009904-bbs2-0047" title="National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases2002;39(2 Suppl 1):S1‐266. [MEDLINE: 11904577] ">KDOQI 2002</a>). People with stage 3 CKD (estimated glomerular filtration rate (eGFR) 30 to 59 mL/min/1.73 m<sup>2</sup>), Stage 4 CKD (eGFR 15 to 29 mL/min/1.73 m<sup>2</sup>) and stage 5 CKD (&lt; 15 mL/min/1.73 m<sup>2</sup>) were included. Patients who required any form of long‐term dialysis were included. We also included people who have a functioning kidney transplant, regardless of their kidney function. </p> </section> <section id="CD009904-sec-0034"> <h5 class="title">Exclusion criteria</h5> <p>Study populations with acute kidney injury were excluded.</p> </section> </section> <section id="CD009904-sec-0035"> <h4 class="title">Types of interventions</h4> <p>Studies of CERA (also known as methoxy poly ethylene‐glycol epoetin beta) by any route (IV or SC), any site of injection, and any dose, compared with epoetin alfa or beta, darbepoetin alfa, placebo, or no treatment, were included. The following comparisons were considered for inclusion. </p> <p> <ul id="CD009904-list-0001"> <li> <p>CERA versus placebo or no treatment</p> </li> <li> <p>CERA versus darbepoetin alfa</p> </li> <li> <p>CERA versus epoetin alfa or beta</p> </li> <li> <p>CERA versus CERA with differing strategies for administration (for example: higher versus lower doses; IV versus SC administration; longer versus shorter dosing intervals; higher versus lower target haemoglobin levels). </p> </li> </ul> </p> <p>We excluded studies that compared CERA with another active treatment for anaemia, including blood transfusion or iron supplementation. </p> </section> <section id="CD009904-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD009904-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009904-list-0002"> <li> <p>Clinical outcomes</p> <ul id="CD009904-list-0003"> <li> <p>One or more major adverse cardiovascular events (myocardial infarction; stroke; heart failure; need for any revascularisation including coronary, carotid or peripheral vascular) </p> </li> <li> <p>One or more hospital admissions (all‐cause, cardiovascular, vascular access)</p> </li> <li> <p>Vascular access thrombosis (≥ 1 events)</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Cancer (onset of new documented cancer, or as defined by the investigators).</p> </li> </ul> </li> </ul> <ul id="CD009904-list-0004"> <li> <p>Quality of life</p> <ul id="CD009904-list-0005"> <li> <p>End of treatment scores according to any measurement tool. If studies report heterogeneous outcomes, we tabulated the results when meta‐analysis was not possible. </p> </li> </ul> </li> <li> <p>Adverse events</p> </li> </ul> <ul class="plain" id="CD009904-list-0006"> <li> <ul id="CD009904-list-0007"> <li> <p>Seizures (≥1 event)</p> </li> <li> <p>Hyperkalaemia (≥1 event)</p> </li> <li> <p>Hypertension (as defined by investigators; one or more events requiring additional antihypertensive medication) (≥ 1 event) </p> </li> <li> <p>Injection‐related events (e.g. infection, lipodystrophy, pain).</p> </li> </ul> </li> </ul> </p> </section> <section id="CD009904-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009904-list-0008"> <li> <p>Achieving and maintaining haemoglobin levels/iron status</p> </li> </ul> <ul class="plain" id="CD009904-list-0009"> <li> <ul id="CD009904-list-0010"> <li> <p>Number of participants achieving target haemoglobin levels (as defined by study investigators)</p> </li> <li> <p>Time to achieve target haemoglobin levels (days)</p> </li> <li> <p>Mean change in haemoglobin (in g/L) or haematocrit levels (%) at end of treatment</p> </li> <li> <p>Number of participants requiring one or more red cell transfusions during follow‐up</p> </li> <li> <p>Number of individuals requiring iron supplementation during follow‐up</p> </li> <li> <p>Number of patients with haemoglobin levels falling outside the haemoglobin target range (as defined by investigators) on one or more occasions during follow‐up </p> </li> <li> <p>Number of participants requiring one or more increases in dose during follow‐up</p> </li> <li> <p>Number of participants requiring one or more decreases in dose during follow‐up</p> </li> <li> <p>Dose of epoetin at end of follow‐up</p> </li> <li> <p>Change in dose of epoetin at end of follow‐up</p> </li> <li> <p>Serum ferritin (µg/L) at end of follow‐up</p> </li> <li> <p>Percent transferrin saturation (%) at end of follow‐up.</p> </li> </ul> </li> </ul> <ul id="CD009904-list-0011"> <li> <p>Progression of CKD in participants with CKD not yet requiring RRT (dialysis or kidney transplantation) </p> <ul id="CD009904-list-0012"> <li> <p>End of treatment eGFR (mL/min/1.73 m<sup>2</sup>) </p> </li> <li> <p>Change in GFR at end of follow‐up</p> </li> <li> <p>Number of participants who experienced doubling of SCr or who develop ESKD (eGFR &lt; 15 mL/min/1.73 m<sup>2</sup>) or requiring RRT. </p> </li> </ul> </li> </ul> <ul id="CD009904-list-0013"> <li> <p>Other</p> <ul id="CD009904-list-0014"> <li> <p>End of treatment left ventricular mass (described using any diagnostic tool including magnetic resonance imaging or echocardiography (g or g/m<sup>2</sup>)) </p> </li> <li> <p>C‐reactive protein (mg/L) at end of follow‐up.</p> </li> </ul> </li> </ul> </p> <p>We tabulated any other adverse events identified in the available studies.</p> </section> </section> </section> <section id="CD009904-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009904-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> to 13 June 2017 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD009904-list-0015"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD009904-sec-0096">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD009904-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD009904-list-0016"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD009904-sec-0042"> <h3 class="title" id="CD009904-sec-0042">Data collection and analysis</h3> <section id="CD009904-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts were screened independently by two authors who discarded studies that are not applicable; however, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and if necessary the full text of these studies, to determine which satisfied the inclusion criteria. </p> <p>Studies reported in non‐English language journals were translated before assessment.</p> </section> <section id="CD009904-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes are only published in earlier versions these data were used. Any discrepancy between published versions was to be highlighted. Any further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review. Disagreements were resolved by consultation among all authors. </p> <p>Two authors independently used standardised data forms to extract the following data.</p> <p> <ul id="CD009904-list-0017"> <li> <p>Study design (parallel or cross‐over, risks of bias, duration, sample size, non‐randomised co‐interventions, location, number of study centres) </p> </li> <li> <p>Participants (source, stage of CKD or time on dialysis, type of dialysis, age, gender)</p> </li> <li> <p>Interventions (generic name, dose, dose interval, mode of administration, epoetin‐naive or previous epoetin use, mean or median dose (and range), target haemoglobin level) </p> </li> <li> <p>Outcomes as described (<a href="#CD009904-sec-0036">Types of outcome measures</a>) </p> </li> </ul> </p> </section> <section id="CD009904-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed using the risk of bias assessment tool (<a href="./references#CD009904-bbs2-0044" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (<i>see</i><a href="./appendices#CD009904-sec-0097">Appendix 2</a>). </p> <p> <ul id="CD009904-list-0018"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD009904-list-0019"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> <p>We made explicit judgements regarding whether studies were at high risk of bias according to the criteria provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009904-bbs2-0044" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009904-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (mortality, cardiovascular events, hospitalisation, vascular access thrombosis, adverse events) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (quality of life, haemoglobin and biochemical variables), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales had been used. </p> <section id="CD009904-sec-0047"> <h5 class="title">Meta‐analysis of change scores</h5> <p>We combined change‐from‐baseline and final value scores (haemoglobin levels) in a meta‐analysis using the MD method in RevMan. We placed end‐of‐treatment values and change‐from‐baseline scores in subgroups for clarity and summarised these treatment effects using random‐effects meta‐analysis. </p> </section> <section id="CD009904-sec-0048"> <h5 class="title">Imputing standard deviation</h5> <p>We imputed a change‐from‐baseline standard deviation using an imputed correlation coefficient when sufficient data are available. We conducted sensitivity analyses when possible to evaluate the effect of imputing missing standard deviation data in our meta‐analysis. </p> </section> </section> <section id="CD009904-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>We included only data from the first period of treatment in cross‐over studies (<a href="./references#CD009904-bbs2-0044" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Data in different metrics were analysed by converting reported values to International System of Units (SI) units. The final results were presented in SI units with conventional units in parentheses. </p> </section> <section id="CD009904-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>If possible, data for each specified outcome was evaluated regardless of whether the analysis was based on intention‐to‐treat or completeness to follow‐up. In particular, dropout rates were investigated and reported in detail such as drop out due to excessive haemoglobin levels, treatment failure, death, transplantation, withdrawal of consent, or loss to follow‐up. When data were unavailable or not reported in an extractable format, we contacted the original investigators to request the missing data. We assessed all studies for risks of bias due to incomplete reporting of results. </p> </section> <section id="CD009904-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi<sup>2</sup> test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I<sup>2</sup> test (<a href="./references#CD009904-bbs2-0043" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I<sup>2</sup> values of 25%, 50% and 75% were considered to correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD009904-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>We interrogated for asymmetries in the inverted funnel plots (that is, for systematic differences in the effect sizes between more precise and less precise studies using the original and modified Egger tests (<a href="./references#CD009904-bbs2-0042" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. [MEDLINE: 16345038] ">Harbord 2006</a>) and the Begg and Mazumdar correlation test (<a href="./references#CD009904-bbs2-0034" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088‐101. [MEDLINE: 7786990] ">Begg 1994</a>). There are many potential explanations for why an inverted funnel plot may be asymmetric, including chance, heterogeneity, publication and reporting bias (<a href="./references#CD009904-bbs2-0065" title="TerrinN , SchmidCH , LauJ . In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. Journal of Clinical Epidemiology2005;58(9):894‐901. [MEDLINE: 16085192] ">Terrin 2005</a>). We refrained from judging funnel plot asymmetries based on visual inspection because this has been shown to be misleading in empirical research (<a href="./references#CD009904-bbs2-0051" title="LauJ , IoannidisJP , TerrinN , SchmidCH , OlkinI . The case of the misleading funnel plot. BMJ2006;333(7568):597‐600. [MEDLINE: 16974018] ">Lau 2006</a>). Publication bias was also evaluated by testing the robustness of the results according to publications, namely publication as a full manuscript in a peer reviewed journal versus studies published as abstracts/text/letters/editorials. </p> </section> <section id="CD009904-sec-0053"> <h4 class="title">Data synthesis</h4> <p>Treatment effects were summarised using the random‐effects model but the fixed‐effect model was also used to ensure robustness of the model chosen and susceptibility to outliers. We qualitatively summarised data where insufficient data are available for meta‐analysis. Qualitative review was conducted for adverse events and quality of life outcomes. We determined the applicability of the results to individual patients (risk groups) using the baseline risk of the outcomes obtained from observational studies within an equivalent population together with the RR and 95% CI to calculate absolute risks for specific patient populations, where possible. </p> </section> <section id="CD009904-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analysis to explore possible sources of heterogeneity (such as participants, interventions and study quality), however insufficient data observations were available to conduct these analyses. </p> </section> <section id="CD009904-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were planned to explore the robustness of findings to key decisions in the review process; however there were insufficient data observations to allow such analyses to be undertaken. </p> <section id="CD009904-sec-0056"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD009904-bbs2-0060" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD009904-bbs2-0040" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD009904-bbs2-0061" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables: </p> <p> <ul id="CD009904-list-0020"> <li> <p>All‐cause mortality</p> </li> <li> <p>One or more red cell transfusions</p> </li> <li> <p>Vascular access thrombosis</p> </li> <li> <p>Hypertension</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009904-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009904-sec-0057"></div> <section id="CD009904-sec-0058"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009904-sec-0101" title="">Characteristics of included studies</a>; <a href="./references#CD009904-sec-0102" title="">Characteristics of excluded studies</a><a href="./references#CD009904-sec-0104" title="">Characteristics of ongoing studies</a>. </p> <section id="CD009904-sec-0059"> <h4 class="title">Results of the search</h4> <p>Our search retrieved 123 reports of studies. After title and abstract review we excluded 13 records and we assessed the full text of the remaining 110 articles. We identified 27 studies (103 records; 5410 participants) that met our inclusion criteria (<a href="#CD009904-fig-0001">Figure 1</a>). Three ongoing studies (<a href="./references#CD009904-bbs2-0030" title="NCT00773513 . A randomized, open label study to assess all‐cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs. www.clinicaltrials.gov/ct2/show/NCT00773513 (first received 15 October 2008). ">NCT00773513</a>; <a href="./references#CD009904-bbs2-0031" title="IshikawaE . Methoxy polyethylene glycol‐epoetin beta once a month versus darbepoetin alfa once a week for treatment of anemia in hemodialysis patients: a randomized, multicenter, open‐label trial. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view cgi?recptno=R000009496 (first received 6 January 2012). ">UMIN000008073</a>; <a href="./references#CD009904-bbs2-0032" title="MitsuikiK . Investigation of responses to erythropoiesis stimulating agents (ESA) for the initial treatment of renal anemia in patients with chronic kidney disease. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view cgi?recptno=R000011078 (first received 4 December 2012). ">UMIN000009472</a>) and one study awaiting classification (<a href="./references#CD009904-bbs2-0029" title="WarwickerP . A randomised, controlled, open‐label, multi‐center, parallel‐group study to demonstrate the efficacy and safety of RO0503821 when administered with pre‐filled syringes for the maintenance treatment of anaemia in patients with chronic kidney disease. National Research Register, UK [www.nrr.nhs.uk/]2004. [CENTRAL: CN‐00487652] ">N0107151969</a>) will be assessed in a future update of this review. </p> <div class="figure" id="CD009904-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009904-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009904-sec-0060"> <h4 class="title">Included studies</h4> <p>Of the 27 included studies, 26 were parallel designed studies (<a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a>, <a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a>; <a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0011" title="Kakimoto‐ShinoM , ToyaY , KujiT , FujikawaT , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis &amp; Dialysis2014;18(5):421‐6. [MEDLINE: 24456328] KujiT , FujikawaT , Kakimoto‐ShinoM , ShibataK , ToyaY , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i244‐5. [EMBASE: 71075732] ">Kakimoto‐Shino 2014</a>; <a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a>; <a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>; <a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a>; <a href="./references#CD009904-bbs2-0016" title="LocatelliF , ChoukrounG , TrumanM , WiggenhauserA , FliserD . Once‐monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis‐dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy2016;33(4):610‐25. [MEDLINE: 26965694] NCT00717821 . A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). ">NCT00717821</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>; <a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>; <a href="./references#CD009904-bbs2-0026" title="ToidaT , SatoY , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii499‐iii500. [EMBASE: 71492907] ToidaT , SatoY , ShibataN , KitamuraK , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification2014;38(3‐4):174‐9. [MEDLINE: 25502179] ">Toida 2014</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>), and one was a cross‐over study (<a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>). </p> <p>No formal sample size calculation was undertaken in nine studies (33%) (<a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0011" title="Kakimoto‐ShinoM , ToyaY , KujiT , FujikawaT , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis &amp; Dialysis2014;18(5):421‐6. [MEDLINE: 24456328] KujiT , FujikawaT , Kakimoto‐ShinoM , ShibataK , ToyaY , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i244‐5. [EMBASE: 71075732] ">Kakimoto‐Shino 2014</a>; <a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>;<a href="./references#CD009904-bbs2-0026" title="ToidaT , SatoY , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii499‐iii500. [EMBASE: 71492907] ToidaT , SatoY , ShibataN , KitamuraK , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification2014;38(3‐4):174‐9. [MEDLINE: 25502179] ">Toida 2014</a>). </p> <p>Seven studies enrolled 1273 participants in earlier stages of CKD (<a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a>; <a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>); 19 studies included 4209 patients on dialysis (<a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a>; <a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a>; <a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009904-bbs2-0011" title="Kakimoto‐ShinoM , ToyaY , KujiT , FujikawaT , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis &amp; Dialysis2014;18(5):421‐6. [MEDLINE: 24456328] KujiT , FujikawaT , Kakimoto‐ShinoM , ShibataK , ToyaY , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i244‐5. [EMBASE: 71075732] ">Kakimoto‐Shino 2014</a>; <a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a>; <a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>; <a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0016" title="LocatelliF , ChoukrounG , TrumanM , WiggenhauserA , FliserD . Once‐monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis‐dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy2016;33(4):610‐25. [MEDLINE: 26965694] NCT00717821 . A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). ">NCT00717821</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009904-bbs2-0026" title="ToidaT , SatoY , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii499‐iii500. [EMBASE: 71492907] ToidaT , SatoY , ShibataN , KitamuraK , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification2014;38(3‐4):174‐9. [MEDLINE: 25502179] ">Toida 2014</a>) and one study provided data for 71 kidney transplant recipients (<a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>). No data were available for children. </p> <p>Twenty‐two of 27 studies (<a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a>; <a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a>; <a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0011" title="Kakimoto‐ShinoM , ToyaY , KujiT , FujikawaT , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis &amp; Dialysis2014;18(5):421‐6. [MEDLINE: 24456328] KujiT , FujikawaT , Kakimoto‐ShinoM , ShibataK , ToyaY , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i244‐5. [EMBASE: 71075732] ">Kakimoto‐Shino 2014</a>; <a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>; <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>; <a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>; <a href="./references#CD009904-bbs2-0026" title="ToidaT , SatoY , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii499‐iii500. [EMBASE: 71492907] ToidaT , SatoY , ShibataN , KitamuraK , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification2014;38(3‐4):174‐9. [MEDLINE: 25502179] ">Toida 2014</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>) provided data that could be included in our meta‐analyses. </p> <p>Median follow‐up was 24 weeks, ranging from 8 to 96 weeks. The average age of participants ranged from 53.4 to 73.4 years. </p> <section id="CD009904-sec-0061"> <h5 class="title">CERA versus epoetin alfa or beta</h5> <p>Nine studies compared CERA with epoetin alfa or beta in 2339 participants (range 34 to 623 participants) (<a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a>; <a href="./references#CD009904-bbs2-0011" title="Kakimoto‐ShinoM , ToyaY , KujiT , FujikawaT , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis &amp; Dialysis2014;18(5):421‐6. [MEDLINE: 24456328] KujiT , FujikawaT , Kakimoto‐ShinoM , ShibataK , ToyaY , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i244‐5. [EMBASE: 71075732] ">Kakimoto‐Shino 2014</a>; <a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>). Two of these studies were published in abstract‐form only (<a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>). Eight studies enrolled participants receiving dialysis (<a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a>; <a href="./references#CD009904-bbs2-0011" title="Kakimoto‐ShinoM , ToyaY , KujiT , FujikawaT , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis &amp; Dialysis2014;18(5):421‐6. [MEDLINE: 24456328] KujiT , FujikawaT , Kakimoto‐ShinoM , ShibataK , ToyaY , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i244‐5. [EMBASE: 71075732] ">Kakimoto‐Shino 2014</a>; <a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>; <a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a>), and one included patients not requiring dialysis (<a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>). No data were available for kidney transplant recipients. </p> <p>The mean age of participants ranged from 53.4 to 68.1 years. Treatment duration ranged between 16 and 52 weeks. Haemoglobin levels targeted by treatment ranged between 10 and 13.5 g/dL. </p> </section> <section id="CD009904-sec-0062"> <h5 class="title">CERA versus darbepoetin alfa</h5> <p>Nine study compared CERA with darbepoetin alfa in 4143 participants (range 20 to 490 participants) (<a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a>; <a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>). Four studies included patients not requiring dialysis (<a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a>), four studies enrolled patients on dialysis (<a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>) and one study enrolled kidney transplant recipients (<a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>). </p> <p>The mean age of participants varied from 55.5 to 73.4 years. Treatment duration ranged between 8 and 52 weeks. Haemoglobin levels targeted by treatment ranged between 10 and 13.5 g/dL. </p> </section> <section id="CD009904-sec-0063"> <h5 class="title">CERA versus epoetin alfa or beta or versus darbepoetin alfa</h5> <p>Two studies compared CERA with epoetin alfa or beta and with darbepoetin alfa in 748 participants receiving dialysis (<a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a>; <a href="./references#CD009904-bbs2-0016" title="LocatelliF , ChoukrounG , TrumanM , WiggenhauserA , FliserD . Once‐monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis‐dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy2016;33(4):610‐25. [MEDLINE: 26965694] NCT00717821 . A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). ">NCT00717821</a>). Treatment duration ranged between 24 and 40 weeks. Haemoglobin levels target was 11 to 12 g/dL in one of the two studies (<a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a>). </p> </section> <section id="CD009904-sec-0064"> <h5 class="title">Frequency of CERA administration</h5> <p>Three studies compared once with twice monthly CERA administration in 878 participants on dialysis (<a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0026" title="ToidaT , SatoY , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii499‐iii500. [EMBASE: 71492907] ToidaT , SatoY , ShibataN , KitamuraK , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification2014;38(3‐4):174‐9. [MEDLINE: 25502179] ">Toida 2014</a>). </p> <p>The mean age of participants ranged from 59 and 66 years. Treatment duration ranged between 8 and 52 weeks. Haemoglobin levels targeted by treatment ranged between 10 and 13.5 g/dL. </p> </section> <section id="CD009904-sec-0065"> <h5 class="title">Different CERA doses</h5> <p>Five studies compared higher with lower CERA doses in 424 participants (<a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>). Of these, four studies were conducted in dialysis patients (<a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a>), and one in patients not receiving dialysis (<a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>). </p> <p>None of these studies reported the mean age of participants. Treatment duration ranged from 12 to 28 weeks. </p> <p><b>CERA versus placebo</b> </p> <p>One study compared CERA with placebo (<a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>) in 241 stage 3 CKD patients with a mean age of 63 years. Treatment duration was 24 months. </p> </section> </section> <section id="CD009904-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded one study which was of short duration (<a href="./references#CD009904-bbs2-0028" title="MacdougallIC , ReignerB , DoughertyFC . Consistent pharmacokinetic properties of CERA (Continuous Erythropoietin Receptor Activator) in healthy volunteers and in patients with CKD) [abstract no: 89]. American Journal of Kidney Diseases2006;47(4):A41. [CENTRAL: CN‐00583919] MacdougallIC , RobsonR , OpatrnaS , LiogierX , PannierA , JordanP , et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1211‐5. [MEDLINE: 17699350] MacdougallIC , RobsonR , OpatrnaS , LiogierX , PannierA , ReignerB , et al. Pharmacologic profile of CERA (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients (pts) following intravenous (IV) and subcutaneous (SC) administration [abstract no: SA‐PO926]. Journal of the American Society of Nephrology2005;16:759A. [CENTRAL: CN‐00795029] ">Macdougall 2006</a>). </p> </section> </section> <section id="CD009904-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD009904-fig-0002">Figure 2</a> and <a href="#CD009904-fig-0003">Figure 3</a> summarise the risk of bias assessment for the included studies. </p> <div class="figure" id="CD009904-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009904-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009904-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009904-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009904-sec-0068"> <h4 class="title">Allocation</h4> <section id="CD009904-sec-0069"> <h5 class="title">Random sequence generation</h5> <p>Four studies (15%) were judged to be at low risk of selection bias due to appropriate random sequence generation: one compared CERA with epoetin (<a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>), two CERA with darbepoetin (<a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>), and one CERA with placebo (<a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>). The risk of bias was high in three studies (11%) comparing different doses of CERA (<a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>) while the remaining 20 studies (74%) did not provide sufficient information to assess risk (unclear risk). </p> </section> <section id="CD009904-sec-0070"> <h5 class="title">Allocation concealment</h5> <p>Four studies (15%) reported adequate methods for allocation concealment, they were all comparing CERA with darbepoetin (<a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>). The risk of bias was high in three studies (11%) (<a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>) all comparing different doses of CERA. The remaining 20 studies (74%) did not provide enough information (unclear risk). </p> </section> </section> <section id="CD009904-sec-0071"> <h4 class="title">Blinding</h4> <section id="CD009904-sec-0072"> <h5 class="title">Performance bias</h5> <p>Two studies (7%) were judged to be low risk of performance bias (<a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a>; <a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>). Twenty‐three studies (85%) were open‐label and therefore at high risk of bias due to absence of blinding of study personnel and patients. The remaining two studies did not provide enough information (unclear risk) (<a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0026" title="ToidaT , SatoY , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii499‐iii500. [EMBASE: 71492907] ToidaT , SatoY , ShibataN , KitamuraK , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification2014;38(3‐4):174‐9. [MEDLINE: 25502179] ">Toida 2014</a>). </p> </section> <section id="CD009904-sec-0073"> <h5 class="title">Detection bias</h5> <p>There was insufficient information to assess detection bias in all of the included studies (unclear risk). </p> </section> </section> <section id="CD009904-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>In seven studies (26%), data to identify loss to follow‐up were not provided (<a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a>; <a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0016" title="LocatelliF , ChoukrounG , TrumanM , WiggenhauserA , FliserD . Once‐monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis‐dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy2016;33(4):610‐25. [MEDLINE: 26965694] NCT00717821 . A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). ">NCT00717821</a>; <a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>). Four studies (15%) were judged to meet the criteria for low risk of attrition bias (below 10% of randomised patients not available for inclusion in analyses) (<a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>). The remaining 16 studies were at high risk of attrition bias. </p> <p>In each treatment comparison, two of the nine studies comparing CERA with darbepoetin (<a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>), one of the nine studies comparing CERA with epoetin (<a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>), one of the six studies comparing differing doses (<a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>) and none of the studies comparing differing frequencies were at low risk of bias. </p> </section> <section id="CD009904-sec-0075"> <h4 class="title">Selective reporting</h4> <p>Outcome of interest (mortality, haemoglobin level, mean dose, blood cell transfusions, vascular access thrombosis, hypertension) were reported in eight studies (30%) (low risk of bias) (<a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>; <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>). </p> <p>Seventeen studies (63%) were considered at high risk of bias (<a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a>; <a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a>; <a href="./references#CD009904-bbs2-0009" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009904-bbs2-0010" title="FurukawaT , OkadaK , AbeM , TeiR , OikawaO , MaruyamaN , et al. Randomized controlled trial of darbepoetin alpha versus continuous erythropoietin receptor activator injected subcutaneously once every four weeks in patients with chronic kidney disease at the pre‐dialysis stage. International Journal of Molecular Sciences2015;16(12):30181‐9. [MEDLINE: 26694377] ">Furukawa 2015</a>; <a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a>; <a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0016" title="LocatelliF , ChoukrounG , TrumanM , WiggenhauserA , FliserD . Once‐monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis‐dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy2016;33(4):610‐25. [MEDLINE: 26965694] NCT00717821 . A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). ">NCT00717821</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0018" title="OtsukaT , SakaiY , YuiS , SukegawaM , SuzukiA , MugishimaK , et al. Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis. Nihon Ika Daigaku Zasshi [Journal of Nippon Medical School]2015;82(1):21‐6. [MEDLINE: 25797871] ">Otsuka 2015</a>; <a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>; <a href="./references#CD009904-bbs2-0026" title="ToidaT , SatoY , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii499‐iii500. [EMBASE: 71492907] ToidaT , SatoY , ShibataN , KitamuraK , FujimotoS . A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification2014;38(3‐4):174‐9. [MEDLINE: 25502179] ">Toida 2014</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>); the remaining tow studies did not report sufficient information for judgment (<a href="./references#CD009904-bbs2-0011" title="Kakimoto‐ShinoM , ToyaY , KujiT , FujikawaT , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis &amp; Dialysis2014;18(5):421‐6. [MEDLINE: 24456328] KujiT , FujikawaT , Kakimoto‐ShinoM , ShibataK , ToyaY , UmemuraS . Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin activator administration in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i244‐5. [EMBASE: 71075732] ">Kakimoto‐Shino 2014</a>;; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>). </p> <p>Results were only published in clinicaltrial.gov for <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a> and only as part of a pooled analysis of 13, phase III studies for <a href="./references#CD009904-bbs2-0016" title="LocatelliF , ChoukrounG , TrumanM , WiggenhauserA , FliserD . Once‐monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis‐dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy2016;33(4):610‐25. [MEDLINE: 26965694] NCT00717821 . A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). ">NCT00717821</a>. </p> <p>Three studies were only reported as conference proceedings (<a href="./references#CD009904-bbs2-0014" title="MeierP . Efficacy of intravenous CERA administered once monthly compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: 65]. Swiss Medical Weekly2008;138(Suppl 167):22S. MeierP , MeierR . Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end‐stage kidney disease on hemodialysis: a randomized trial [abstract no: M571]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Meier 2008</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0027" title="TsubakiharaY , BesshoM , SuzukiM , JH22757 Study Group. C.E.R.A. administrated subcutaneously (SC) once every four weeks (Q4W) is non‐inferior to epoetin (EPO) once every two weeks (Q2W) in Japanese patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: F167]. NDT Plus2011;4(Suppl 2):4.s2.32. ">Tsubakihara 2011</a>). </p> </section> <section id="CD009904-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>Other potential sources of bias included the following.</p> <p> <ul id="CD009904-list-0021"> <li> <p>Unequal baseline characteristics (3 studies, 11%) (<a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>) </p> </li> <li> <p>Industry sponsor involved in authorship/design/analysis (17 studies, 63%) (<a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a>; <a href="./references#CD009904-bbs2-0005" title="BesarabA , BeyerU , DoughertyFC . Long‐term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W‐PO40127]. Nephrology2005;10(Suppl 1):A312‐3. [CENTRAL: CN‐00747326] BesarabA , SalifuMO , LundeNM , BansalV , FishbaneS , DoughertyFC , et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19‐week, phase II, multicenter, randomized, open‐label, dose‐finding study with a 12‐month extension phase in patients with chronic renal disease. Clinical Therapeutics2007;29(4):626‐39. [MEDLINE: 17617286] DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16285 Study 2007</a>; <a href="./references#CD009904-bbs2-0006" title="DoughertyFC , BeyerU . No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W‐PO40131]. Nephrology2005;10(Suppl 1):A313‐4. [CENTRAL: CN‐00602138] DoughertyFC , BeyerU . Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W‐PO40130]. Nephrology2005;10(Suppl 1):A313. [CENTRAL: CN‐00602137] DoughertyFC , Loghman‐AdhamM , SchultzeN , BeyerU . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v269. [CENTRAL: CN‐00602143] DutkaP , TiloccaP , BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal2006;33(2):138. [CENTRAL: CN‐00602144] LocatelliF , VillaG , AriasM , MarchesiD , DoughertyFC , BeyerU , et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract no: SU‐PO051]. Journal of the American Society of Nephrology2004;15(Oct):543A. [CENTRAL: CN‐00626008] LocatelliF , VillaG , BeyerU , DoughertyFC . Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v261. [CENTRAL: CN‐00602142] LocatelliF , VillaG , deFranciscoAL , AlbertazziA , AdrogueHJ , DoughertyFC , et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research &amp; Opinion2007;23(5):969‐79. [MEDLINE: 17519064] SalifuM , VillaG , DoughertyFC . Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre‐existing conditions [abstract no: 138]. American Journal of Kidney Diseases2006;47(4):A53. [CENTRAL: CN‐00602141] ">BA16286 Study 2007</a>; <a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009904-bbs2-0015" title="NCT00442702 . A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (first received 1 March 2007). ">NCT00442702</a>; <a href="./references#CD009904-bbs2-0016" title="LocatelliF , ChoukrounG , TrumanM , WiggenhauserA , FliserD . Once‐monthly continuous erythropoietin receptor activator (CERA) in patients with hemodialysis‐dependent chronic kidney disease: pooled data from phase III trials. Advances in Therapy2016;33(4):610‐25. [MEDLINE: 26965694] NCT00717821 . A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (first received 16 July 2008). ">NCT00717821</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>; <a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a>; <a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a>; <a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a>; <a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a>; <a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a>; <a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009904-bbs2-0025" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4.s2.32. CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: F164]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] ">TIVOLI Study 2013</a>). </p> </li> </ul> </p> </section> </section> <section id="CD009904-sec-0077"> <h3 class="title" id="CD009904-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD009904-tbl-0001"><b>Summary of findings for the main comparison</b> Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (CKD)</a> </p> <section id="CD009904-sec-0078"> <h4 class="title">CERA versus epoetin alfa or beta</h4> <p>Overall there was low certainty evidence that CERA compared with epoetin alfa or beta had little or no effect on risk of all‐cause mortality (<a href="./references#CD009904-fig-0004" title="">Analysis 1.1</a> (5 studies, 1846 participants): RR 1.07, 95% CI 0.73 to 1.57; I<sup>2</sup> = 0%), major cardiovascular events (<a href="./references#CD009904-fig-0005" title="">Analysis 1.2</a> (1 study, 333 participants): RR 5.09, 95% CI 0.25 to 105.23), cancer (<a href="./references#CD009904-fig-0007" title="">Analysis 1.4</a> (2 studies, 903 participants): RR 0.82, 95% CI 0.18 to 3.67; I<sup>2</sup> = 0%); hypertension (<a href="./references#CD009904-fig-0008" title="">Analysis 1.5</a> (5 studies, 1821 participants): RR 1.01, 95% CI 0.75 to 1.37; I<sup>2</sup> = 34%); blood cell transfusions (<a href="./references#CD009904-fig-0010" title="">Analysis 1.7</a> (5 studies, 1824 participants): RR 1.02, 95% CI 0.72 to 1.46; I<sup>2</sup> = 14%); or one or more hospital admissions (<a href="./references#CD009904-fig-0017" title="">Analysis 1.14</a> (1 study, 94 participants): RR 0.56, 95% CI 0.20 to 1.53). </p> <p>There was low certainty evidence that CERA compared with epoetin alfa or beta, might have little or no effect on risk of vascular access thrombosis (<a href="./references#CD009904-fig-0006" title="">Analysis 1.3</a> (3 studies, 1419 participants): RR 1.09, 95% CI 0.49 to 2.40; I<sup>2</sup> = 71%) and need for iron therapy (<a href="./references#CD009904-fig-0011" title="">Analysis 1.8</a> (2 studies, 437 participants): RR 1.03, 95% CI 0.91 to 1.15; I<sup>2</sup> = 73%) with substantial heterogeneity in the analyses. </p> <p>There was low certainty evidence that CERA compared with epoetin might lead to little or no difference in haemoglobin levels achieved at the end of treatment (<a href="./references#CD009904-fig-0012" title="">Analysis 1.9</a> (6 studies, 1626 participants): MD ‐0.12 g/dL, 95% CI ‐0.34 to 0.10; I<sup>2</sup> = 68%) and mean change in haemoglobin levels at the end of treatment (<a href="./references#CD009904-fig-0013" title="">Analysis 1.10</a> (4 studies, 1510 participants): MD 0.08 g/dL, 95% CI ‐0.04 to 0.19; I<sup>2</sup> = 0%). It was uncertain if the percentage of patients achieving the haemoglobin target (10 to 13.5 g/dL) was increased by CERA treatment compared with epoetin alfa or beta (<a href="./references#CD009904-fig-0014" title="">Analysis 1.11</a> (5 studies, 1133 participants): RR 1.03, 95% CI 0.94 to 1.12; very low certainty evidence; I<sup>2</sup> = 48%) with moderate heterogeneity in the analysis. There was insufficient evidence on whether CERA compared with epoetin decreased the percentage of patients exceeding the haemoglobin target (<a href="./references#CD009904-fig-0015" title="">Analysis 1.12</a> (1 study at high risk of bias, 69 participants): RR 0.65, 95% CI 0.33 to 1.29). The mean dose of CERA at the end of treatment appeared lower than the mean dose of epoetin but the certainty of evidence was low and there was high heterogeneity in the analysis (<a href="./references#CD009904-fig-0016" title="">Analysis 1.13</a> (2 studies, 194 participants): SMD ‐2.11, 95% CI ‐3.60 to ‐0.62; I<sup>2</sup> = 93%). </p> <p>Two studies reported health‐related quality of life measured using the Short Form 36 tool and its Korean version respectively, during 25 weeks of treatment (<a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a>; <a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a>) but did not provide analyses of treatment effects comparing CERA with epoetin (<a href="#CD009904-tbl-0002">Table 1</a>). </p> <div class="table" id="CD009904-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Health‐related quality of life outcomes in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Stage of CKD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Tool</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CERA versus epoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> <p>(HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐form 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinically meaningful changes from baseline (≥ 5 points) to week 13 and week 25 were noted in patients treated with CERA (score changes were reported in figure) </p> <p><b>Comparative effects for CERA versus epoetin on HRQOL were not reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> <p>(HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Korean version of Short‐form 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 13, a meaningful decrease (≥ 5 points) was observed on physical functioning for CERA group. At week 25, mean scores increased on all sub‐scales except role‐emotional for CERA group and clinically meaningful improvements was observed in vitality for CERA group (score changes were reported in figure) </p> <p><b>Comparative effects for CERA versus darbepoetin alfa on HRQOL were not reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CERA versus darbepoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐form 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to baseline, mean scores increased on each of the eight sub scales and summary scores in both treatment groups, representing an improvement in each parameter (score changes were reported in figure). Clinically meaningful improvements from baseline to weeks 13 and 29 (≥ 5 points) were observed for CERA once every 2 week in general health, vitality, role emotional, role physical (week 13 only), and social functioning and for darbepoetin alfa in vitality, role emotional, and role physical </p> <p><b>Comparative effects for CERA versus darbepoetin alfa on HRQOL were not reported</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CERA ‐ continuous erythropoiesis receptor activator; CKD ‐ chronic kidney disease; HD ‐ haemodialysis; HRQOL ‐ Health‐related quality of life; PD peritoneal dialysis </p> </div> </div> <p>Overall a similar incidence of adverse events between groups was reported; these were judged mild to moderate in intensity and mainly not treatment‐related (<a href="#CD009904-tbl-0003">Table 2</a>). </p> <div class="table" id="CD009904-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects reported in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Stage of CKD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA versus epoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse events during the study were mild to moderate, among which thrombosed arteriovenous shunt was considered as the most specific complication to the given medications, nevertheless incidence remained low </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events did not differ between groups (P &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events did not differ between groups (P = 0.12).The most common serious adverse events were sepsis, pneumonia and arteriovenous graft thrombosis. Only 6 patients had serious adverse events that were judged to be treatment‐related (three and two with CERA every 2 and 4 weeks, respectively, and one with epoetin; P = 0.40) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall and frequently reported adverse events during the correction phase were comparable between the two study arms. Serious adverse events were reported 14 events in 10 patients (26.3%) in CERA and 7 events in 6 patients (15.4%) in epoetin beta group. None of them was judged to be related with study drugs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events were hypertension, procedural hypotension (induced by dialysis), nasopharyngitis, headache, and diarrhoea. Most events were mild or moderate in intensity and distributed evenly across groups. The incidence of treatment‐related adverse events was low in all groups (once monthly CERA 6%; twice monthly CERA 4%; epoetin 2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The overall incidence of adverse events was similar between the two treatment groups; at least one adverse event was experienced by 94.5% and 94.6% of patients in the CERA and epoetin groups, respectively. Most events were mild to moderate in intensity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA versus darbepoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse events during the study were mild to moderate, among which thrombosed arteriovenous shunt was considered as the most specific complication to the given medications, nevertheless incidence remained low </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of patients who experienced one or more adverse events was similar between groups and typical of this patient population. The most commonly reported adverse events included hypertension, peripheral oedema, diarrhoea, and nasopharyngitis. Most events were mild or moderate and very few were considered treatment related (CERA 7.5%; darbepoetin alfa 5.6%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most adverse events experienced by patients in each study arm were reported to be mild to moderate intensity, and rates were comparable between the two groups. The most frequently reported adverse events were hypertension, renal impairment, hyperkalaemia, upper respiratory tract infection and constipation. Numerically more patients in the darbepoetin alfa arm experienced resinous adverse events compared with patients in the CERA arm (12% versus 6% respectively). No patient had a serious adverse event that was judged to be treatment related </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events did not differ between groups (P = 0.55). Six were judged to be related to treatment (four with CERA and two with darbepoetin alfa, respectively). Serious adverse events were comparable in the two groups (P = 0.71). The most common serious adverse events were arteriovenous fistula site complication, arteriovenous fistula thrombosis and sepsis. No patient had serious adverse events that was judged to be treatment related </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The overall incidences of adverse and serious adverse events were similar between the two treatment groups and typical of the patient population. The most commonly reported adverse events were diarrhoea, nasopharyngitis and influenza. Serious adverse events were considered to be related to study treatment in one patient in the CERA group (arteriovenous graft thrombosis) and three patients in the darbepoetin group (arteriovenous graft thrombosis, arteriovenous fistula site haemorrhage and cerebral infarction) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA lower versus higher doses</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events were gastrointestinal disorders, infections, nervous system and vascular disorders. Most events were mild or moderate in intensity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The adverse events manifested were similar among the dose groups investigated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events were hypertension, urinary tract infection and kidney failure. The majority of events were mild or moderate in intensity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events with a suspected relation to the study drug occurred in 22% and 16% of patients randomised to CERA and placebo, respectively </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CERA ‐ continuous erythropoiesis receptor activator; CKD ‐ chronic kidney diease; HD ‐ haemodialysis; PD ‐ peritoneal dialysis </p> </div> </div> </section> <section id="CD009904-sec-0079"> <h4 class="title">CERA versus darbepoetin alfa</h4> <p>Overall there was low certainty evidence that CERA compared to darbepoetin alfa had little or no effect on risk of all‐cause mortality (<a href="./references#CD009904-fig-0020" title="">Analysis 2.1</a> (5 studies, 1657 participants): RR 1.11, 95% CI 0.75 to 1.65; I<sup>2</sup> = 0%), cardiovascular mortality (<a href="./references#CD009904-fig-0021" title="">Analysis 2.2</a> (2 studies, 633 participants): RR 1.68, 95% CI 0.74 to 3.78; I<sup>2</sup> = 0%), major cardiovascular events (<a href="./references#CD009904-fig-0022" title="">Analysis 2.3</a> (2 studies, 551 participants): RR 5.56, 95% CI 0.99 to 31.30; I<sup>2</sup> = 0%), hypertension (<a href="./references#CD009904-fig-0023" title="">Analysis 2.4</a> (6 studies, 1725 participants): RR 1.00, 95% CI 0.79 to 1.28; I<sup>2</sup> = 8%), hyperkalaemia (<a href="./references#CD009904-fig-0024" title="">Analysis 2.5</a> (3 studies, 854 participants): RR 1.23, 95% CI 0.63 to 2.39; I<sup>2</sup> = 4%), and need for iron therapy (<a href="./references#CD009904-fig-0034" title="">Analysis 2.15</a> (2 studies, 798 participants): RR 0.99, 95% CI 0.95 to 1.03; I<sup>2</sup> = 0%). </p> <p>There was low certainty evidence that CERA compared with darbepoetin had little or no effect on the risk of blood cell transfusions (<a href="./references#CD009904-fig-0033" title="">Analysis 2.14</a> (6 studies, 1728 participants): RR 0.94, 95% CI 0.55 to 1.61; I<sup>2</sup> = 52%) with substantial heterogeneity in the analysis. </p> <p>There was low certainty evidence that CERA might lead to a little or no effect on the mean change in haemoglobin levels (<a href="./references#CD009904-fig-0027" title="">Analysis 2.8</a> (2 studies, 261 participants): MD 0.18 g/dL, 95% CI ‐0.07 to 0.42; I<sup>2</sup> = 0%) and the haemoglobin levels at the end of treatment (<a href="./references#CD009904-fig-0026" title="">Analysis 2.7</a> (4 studies, 750 participants): MD 0.03, 95% CI ‐0.13 to 0.18; I<sup>2</sup> = 0%) compared to darbepoetin. The percentage of patients achieving the haemoglobin target (10 to 13 g/dL) (<a href="./references#CD009904-fig-0025" title="">Analysis 2.6</a> (5 studies, 1251 participants; RR 1.10, 95% CI 0.93 to 1.29; low certainty evidence; I<sup>2</sup> = 84%) and the mean treatment dose at the end of the follow‐up (<a href="./references#CD009904-fig-0028" title="">Analysis 2.9</a> (4 studies, 632 participants): SMD 0.24, 95% CI ‐0.30 to 0.77; low certainty evidence; I<sup>2</sup> = 85%) seemed to be similar for CERA and darbepoetin alfa with substantial heterogeneity in the analysis of achieving haemoglobin target. </p> <p>One study at moderate risk of bias reported that once monthly CERA treatment compared to twice monthly darbepoetin alfa probably reduced the need for a dose decrease (<a href="./references#CD009904-fig-0032" title="">Analysis 2.13</a> (430 participants): RR 3.84, 95% CI 1.96 to 7.52) and probably avoid a dose increase (<a href="./references#CD009904-fig-0031" title="">Analysis 2.12</a> (430 participants): RR 0.55, 95% CI 0.44 to 0.69) in order to achieve the haemoglobin target (11 to 13 g/dL) over a follow‐up period of 12 months. One study at moderate‐high risk of bias reported that CERA compared with darbepoetin probably reduced the risk of exceeding the haemoglobin target (11 to 13 g/dL) (<a href="./references#CD009904-fig-0029" title="">Analysis 2.10</a> (324 participants): RR 0.84, 95% CI 0.74 to 0.96). There was insufficient evidence to compare CERA to darbepoetin on the time to achieve the haemoglobin target (10 to 12 g/dL) (<a href="./references#CD009904-fig-0030" title="">Analysis 2.11</a> (one study, 71 participants): MD 6.50 days, 95% CI ‐6.38 to 19.38). </p> <p>One study reported health‐related quality of life measured using the Short Form 36 tool during 25 weeks of treatment (<a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>) but did not provide analyses of treatment effects comparing CERA with darbepoetin alfa (<a href="#CD009904-tbl-0002">Table 1</a>). </p> <p>Overall a similar incidence of adverse events between groups was reported; most of these were judged to be not treatment‐related (<a href="#CD009904-tbl-0003">Table 2</a>). </p> </section> <section id="CD009904-sec-0080"> <h4 class="title">CERA once versus twice monthly administration</h4> <p>Overall there was low certainty evidence that CERA administered twice versus once/month had little or no effect on all‐cause mortality (<a href="./references#CD009904-fig-0037" title="">Analysis 3.1</a> (2 studies, 822 participants): RR 0.97, 95% CI 0.56 to 1.66; I<sup>2</sup> =24%), vascular access thrombosis (<a href="./references#CD009904-fig-0038" title="">Analysis 3.2</a> (2 studies, 822 participants): RR 0.93, 95% CI 0.61 to 1.41; I<sup>2</sup> = 0%), hypertension (<a href="./references#CD009904-fig-0039" title="">Analysis 3.3</a> (2 studies, 822 participants): RR 0.85, 95% CI 0.60 to 1.21; I<sup>2</sup> = 0%), hyperkalaemia (<a href="./references#CD009904-fig-0040" title="">Analysis 3.4</a> (1 study, 380 participants): RR 0.50, 95% CI 0.05 to 5.47), haemoglobin levels at the end of treatment (<a href="./references#CD009904-fig-0041" title="">Analysis 3.5</a> (2 studies, 653 participants): MD 0.15 g/dL, 95% CI 0.00 to 0.31; I<sup>2</sup> = 0%), blood cell transfusions (<a href="./references#CD009904-fig-0045" title="">Analysis 3.9</a> (3 studies, 872 participants): RR 0.91, 95% CI 0.51 to 1.62; I<sup>2</sup> =25%), and cancer (<a href="./references#CD009904-fig-0044" title="">Analysis 3.8</a> (1 study, 380 participants): RR 7.0, 95% CI 0.36 to 134.60). </p> <p>It was uncertain whether CERA administered twice versus once monthly might lead to little or no difference in the mean change of haemoglobin levels at the end of treatment (<a href="./references#CD009904-fig-0042" title="">Analysis 3.6</a> (2 studies, 701 participants): MD 0.03 g/dL, 95% CI ‐0.12 to 0.18; I<sup>2</sup> = 1%; low certainty evidence), the percentage of patients achieving the haemoglobin target (11 to 13 g/dL) (<a href="./references#CD009904-fig-0043" title="">Analysis 3.7</a> (1 study at high risk of bias, 381 participants): RR 0.96, 95% CI 0.90 to 1.03), and mean dose at the end of treatment (<a href="./references#CD009904-fig-0046" title="">Analysis 3.10</a> (1 study at unclear risk of bias, 42 participants); MD ‐11.20 µg, 95% CI ‐35.52 to 13.12). </p> </section> <section id="CD009904-sec-0081"> <h4 class="title">CERA higher versus lower doses</h4> <p>There was insufficient evidence to compare lower doses versus higher doses of CERA on the risk of all‐cause mortality (<a href="./references#CD009904-fig-0047" title="">Analysis 4.1</a> (1 study, 42 participants): RR 3.95, 95% CI 0.17 to 91.61), hypertension (<a href="./references#CD009904-fig-0048" title="">Analysis 4.2</a> (2 studies, 89 participants): RR 0.45, 95% CI 0.08 to 2.52; I<sup>2</sup> = 24%), and blood cell transfusions (<a href="./references#CD009904-fig-0049" title="">Analysis 4.3</a> (2 studies, 125 participants): RR 4.16, 95% CI 0.89 to 19.53; I<sup>2</sup> = 67%). </p> <p>There was very low certainty evidence that lower compared to higher doses of CERA might lead to less mean change in haemoglobin levels (<a href="./references#CD009904-fig-0050" title="">Analysis 4.4</a> (4 studies, 250 participants): MD ‐1.26 g/dL, 95% CI ‐1.77 to ‐0.74; I<sup>2</sup> = 73%) with substantial heterogeneity in the analysis. It was unclear whether different doses of CERA had different effect on the probability to achieve the haemoglobin target (<a href="./references#CD009904-fig-0053" title="">Analysis 4.7</a> (1 study at high risk of bias, 47 participants): RR 0.74, 95% CI 0.52 to 1.05) and the need for a dose increase (<a href="./references#CD009904-fig-0052" title="">Analysis 4.6</a> (2 studies, 125 participants); RR 4.16, 95% CI 0.89 to 19.53; very low certainty evidence; I<sup>2</sup> = 69%) or decrease (<a href="./references#CD009904-fig-0051" title="">Analysis 4.5</a> (1 study at high risk of bias, 42 participants): RR 1.00, 95% CI 0.25 to 3.92) to achieve the target. </p> <p>Three studies reported information on adverse events but without comparing their incidence between groups (<a href="#CD009904-tbl-0003">Table 2</a>). </p> </section> <section id="CD009904-sec-0082"> <h4 class="title">CERA versus placebo</h4> <p>There was insufficient evidence to compare CERA and placebo on clinical outcomes. One study (235 participants not requiring dialysis) at moderate‐high risk of bias reported that CERA treatment compared with placebo had little or no effect on the risk of major cardiovascular events (<a href="./references#CD009904-fig-0054" title="">Analysis 5.1</a>: RR 2.97, 95% CI 0.31 to 28.18), cancer (<a href="./references#CD009904-fig-0055" title="">Analysis 5.2</a>: RR 0.99, 95% CI 0.06 to 15.67), hypertension (<a href="./references#CD009904-fig-0056" title="">Analysis 5.3</a>: RR 0.73, 95% CI 0.35 to 1.52), hyperkalaemia (<a href="./references#CD009904-fig-0057" title="">Analysis 5.4</a>: RR 4.96, 95% CI 0.24 to 102.17), and end of treatment eGFR (<a href="./references#CD009904-fig-0058" title="">Analysis 5.5</a> (210 participants): MD ‐0.70 mL/min/1.73 m<sup>2</sup>, 95% CI ‐3.71 to 2.31). </p> <section id="CD009904-sec-0083"> <h5 class="title">Subgroup and sensitivity analyses</h5> <p>While there was evidence of statistical heterogeneity in some meta‐analysis, there were insufficient observations to perform subgroup and/or sensitivity analyses to explore potential sources of heterogeneity. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009904-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009904-sec-0084"></div> <section id="CD009904-sec-0085"> <h3 class="title" id="CD009904-sec-0085">Summary of main results</h3> <p>We found that there was low certainty evidence that CERA compared to epoetin or darbepoetin had little or no effect on patient‐centred outcomes (all‐cause and cause‐specific mortality, major cardiovascular adverse events, cancer, high blood pressure, seizures, dialysis vascular access thrombosis or treatment injection‐related events, blood cell transfusions) among adults with CKD. </p> <p>There was low certainty evidence whether participants receiving CERA experienced different haemoglobin levels on treatment compared to other ESAs. </p> <p>In one study at moderate risk of bias adults receiving once monthly CERA treatment seemed to be more likely to require a dose decrease and less likely to require a dose increase in order to achieve the specified haemoglobin target (11 to 13 g/dL) than participants receiving twice monthly darbepoetin alfa treatment (<a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>); and in one study, at moderate‐high risk of bias, those treated with CERA seemed to be less likely to exceed the haemoglobin target (11 to 13 g/dL) during treatment (<a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>). </p> <p>No evidence was available for the comparative effects of different ESAs on health‐related quality of life. </p> <p>Lower doses of CERA compared to higher doses resulted in a lower haemoglobin change at the end of treatment in five studies but there was substantial heterogeneity in the analysis and the certainty of evidence was very low. </p> <p>There was insufficient evidence to compare CERA and placebo on clinical outcomes. One study of stage 3 CKD patients reported uncertain effect of CERA compared with placebo on risk of major cardiovascular adverse events, cancer, hypertension, hyperkalaemia and change in GFR levels at the end of treatment between groups. We found no studies conducted in children, one study in 71 kidney transplant recipients, and six in earlier stages of CKD (one of which in abstract publication only and two reporting results only on clinicaltrial.gov), making assessments of treatment efficacy and safety in these clinical situations difficult. </p> </section> <section id="CD009904-sec-0086"> <h3 class="title" id="CD009904-sec-0086">Overall completeness and applicability of evidence</h3> <p>We aimed to assess the safety and efficacy of longer‐acting ESAs for treatment of anaemia in people with CKD. This review included only a small number of studies of short duration, lasting approximately six months on average. The short duration of the included studies resulted in inconclusive effects on major cardiovascular outcomes including mortality as well as other side‐effects due to the lack of sufficient power in the available studies, both individually and collectively. This limitation is important as previous analyses have shown increased mortality and cardiovascular endpoints among patients treated with ESAs to a higher haemoglobin target, (<a href="./references#CD009904-bbs2-0055" title="PhrommintikulA , HaasSJ , ElsikM , KrumH . Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta‐analysis. Lancet2007;369(9559):381‐8. [MEDLINE: 17276778] ">Phrommintikul 2007</a>) although it remains uncertain whether this increased complication rate is due to the ESA dose or the haemoglobin levels achieved. Future completion of an ongoing large RCT assessing the comparative effect of CERA and other ESAs on all‐cause mortality and cardiovascular morbidity may add new and more conclusive evidence to the topic. </p> <p>Exploration of any different effects of CERA by severity of CKD, type of dialysis, duration of treatment or haemoglobin level was limited due to the small number of included studies. Evidence of the effectiveness of differing frequency of administration and dose was restricted to adults with CKD stage 5 with largely inconclusive results. Notably, information about quality of life was limited to three studies and comparative analyses comparing CERA with other ESAs were not provided. Therefore, confident conclusions about effects of CERA on health‐related quality of life cannot be drawn. In a previous systematic review of the impact of haemoglobin target levels on health‐related quality of life, only a small and not clinically meaningful improvement in quality of life was observed with a haemoglobin level above 12 g/dL, although reporting of quality of life was frequently incomplete (<a href="./references#CD009904-bbs2-0036" title="ClementFM , KlarenbachS , TonelliM , JohnsonJA , MannsBJ . The impact of selecting a high hemoglobin target level on health‐related quality of life for patients with chronic kidney disease: a systematic review and meta‐analysis. Archives of Internal Medicine2009;169(12):1104‐12. [MEDLINE: 19546410] ">Clement 2009</a>). </p> </section> <section id="CD009904-sec-0087"> <h3 class="title" id="CD009904-sec-0087">Quality of the evidence</h3> <p>There was considerable under‐reporting of study design and conduct which led to lower confidence in the results due to potential or unclear risks of bias in the included studies. Data comparing CERA with epoetin alfa or beta were generally at high or unclear risk of bias while data comparing CERA with darbepoetin alfa were at lower risk of bias. Information about the effects of differing frequency of administration and dose were limited by studies commonly using inadequate methods for allocation concealment, and selectively reporting of outcomes. Any inconsistency in treatment effects between studies (principally seen for outcomes related to haemoglobin levels or concomitant iron or blood transfusion use) were likely to relate to differing clinical approaches to anaemia management but the sources could not be explored statistically due to lack of a sufficient number of studies. </p> </section> <section id="CD009904-sec-0088"> <h3 class="title" id="CD009904-sec-0088">Potential biases in the review process</h3> <p>This review was carried out using standard Cochrane methods to minimise bias inherent in the review process. We screened for eligible studies and assessed for risks of bias by two authors working independently. The key limitations in this review relate to the number of studies available, the treatment duration, and the risks of bias due to individual study limitations. First, relatively few data were available for most treatment comparisons resulting in inconclusive evidence for many outcomes including mortality and cardiovascular events. Second, the studies differed in management of anaemia including co‐interventions leading to potential heterogeneity in treatment effects, which could not be further explored. Finally, data for patient outcomes including mortality and health‐related quality of life were often reported ad hoc and reduced our confidence in the reliability of these treatment effects. This was particularly the case for quality of life assessments. </p> </section> <section id="CD009904-sec-0089"> <h3 class="title" id="CD009904-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>The finding that different ESAs have uncertain effects on patient‐level outcomes compared with each other is similar to the conclusions of a recent Cochrane network meta‐analysis of all ESA drugs in the setting of kidney disease (<a href="./references#CD009904-bbs2-0054" title="PalmerSC , SaglimbeneV , MavridisD , SalantiG , CraigJC , TonelliM , et al. Erythropoiesis‐stimulating agents for anaemia in adults with chronic kidney disease: a network meta‐analysis. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD010590.pub2] ">Palmer 2014</a>), which also observed a lack of difference among ESA types. The similar in findings between this review and the previous network meta‐analysis, despite different methodologies, strengthens confidence in the findings of both studies. In a previous systematic review directly comparing darbepoetin alfa with epoetins, there were few studies and aggregated data were insufficient to identify any treatment effects on mortality (<a href="./references#CD009904-bbs2-0068" title="Wilhelm‐LeenER , WinkelmayerWC . Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta‐analysis. American Journal of Kidney Diseases2015;66(1):69‐74. [MEDLINE: 25636816] ">Wilhelm‐Leen 2015</a>), a finding that was similar to a longer‐term analysis in USA dialysis facilities (<a href="./references#CD009904-bbs2-0070" title="WinkelmayerWC , ChangTI , MitaniAA , Wilhelm‐LeenER , DingV , ChertowGM , et al. Longer‐term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi‐experimental cohort study. American Journal of Kidney Diseases2015;66(1):106‐13. [MEDLINE: 25943715] ">Winkelmayer 2015</a>). Similarly, a recent systematic review of CERA versus darbepoetin alfa in people with non‐dialysis dependent CKD reported similar serious adverse events in each treatment group (<a href="./references#CD009904-bbs2-0033" title="AlsalimyN , AwaisuA . Methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa for anemia in non‐dialysis‐dependent CKD: a systematic review. International Journal of Clinical Pharmacy2014;36(6):1115‐25. [MEDLINE: 25288147] ">Alsalimy 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009904-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009904-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009904-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009904-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 1 All‐cause mortality." data-id="CD009904-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 2 Major adverse cardiovascular event." data-id="CD009904-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 2 Major adverse cardiovascular event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 3 Vascular access thrombosis." data-id="CD009904-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 3 Vascular access thrombosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 4 Cancer." data-id="CD009904-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 4 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 5 Hypertension." data-id="CD009904-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 5 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 6 Hyperkalaemia." data-id="CD009904-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 6 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 7 Blood transfusion." data-id="CD009904-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 7 Blood transfusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 8 Iron supplementation." data-id="CD009904-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 8 Iron supplementation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 9 Haemoglobin (end of treatment)." data-id="CD009904-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 9 Haemoglobin (end of treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 10 Haemoglobin (change during treatment)." data-id="CD009904-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 10 Haemoglobin (change during treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 11 Achieved haemoglobin level target." data-id="CD009904-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 11 Achieved haemoglobin level target. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 12 Exceeding haemoglobin level target." data-id="CD009904-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 12 Exceeding haemoglobin level target. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 13 Epoetin dose (end of treatment)." data-id="CD009904-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 13 Epoetin dose (end of treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 14 One or more hospital admissions." data-id="CD009904-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 14 One or more hospital admissions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 15 Serum ferritin at end of follow‐up." data-id="CD009904-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 15 Serum ferritin at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CERA versus epoetin alfa or beta, Outcome 16 Transferrin saturation at end of follow‐up." data-id="CD009904-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 CERA versus epoetin alfa or beta, Outcome 16 Transferrin saturation at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 1 All‐cause mortality." data-id="CD009904-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 2 Cardiovascular mortality." data-id="CD009904-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 2 Cardiovascular mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 3 Major adverse cardiovascular event." data-id="CD009904-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 3 Major adverse cardiovascular event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 4 Hypertension." data-id="CD009904-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 4 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 5 Hyperkalaemia." data-id="CD009904-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 5 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 6 Achieved haemoglobin level target." data-id="CD009904-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 6 Achieved haemoglobin level target.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 7 Haemoglobin (end of treatment)." data-id="CD009904-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 7 Haemoglobin (end of treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 8 Haemoglobin (change during treatment)." data-id="CD009904-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 8 Haemoglobin (change during treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 9 Epoetin dose (end of treatment)." data-id="CD009904-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 9 Epoetin dose (end of treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 10 Exceeding haemoglobin level target." data-id="CD009904-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 10 Exceeding haemoglobin level target. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 11 Time within the target haemoglobin range." data-id="CD009904-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 11 Time within the target haemoglobin range. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 12 Need for one or more dose increase." data-id="CD009904-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 12 Need for one or more dose increase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 13 Need for one or more dose decrease." data-id="CD009904-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 13 Need for one or more dose decrease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 14 Blood transfusion." data-id="CD009904-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 14 Blood transfusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 15 Iron supplementation." data-id="CD009904-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 15 Iron supplementation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 16 Serum ferritin at the end of follow‐up." data-id="CD009904-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 16 Serum ferritin at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CERA versus darbepoetin alfa, Outcome 17 Transferrin saturation at end of follow‐up." data-id="CD009904-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 CERA versus darbepoetin alfa, Outcome 17 Transferrin saturation at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 1 All‐cause mortality." data-id="CD009904-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 2 Vascular access thrombosis." data-id="CD009904-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 2 Vascular access thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 3 Hypertension." data-id="CD009904-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 3 Hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 4 Hyperkalaemia." data-id="CD009904-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 4 Hyperkalaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 5 Haemoglobin (end of treatment)." data-id="CD009904-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 5 Haemoglobin (end of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 6 Haemoglobin (change during treatment)." data-id="CD009904-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 6 Haemoglobin (change during treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 7 Achieved haemoglobin level target." data-id="CD009904-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 7 Achieved haemoglobin level target. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 8 Cancer." data-id="CD009904-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 8 Cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 9 Blood transfusion." data-id="CD009904-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 9 Blood transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 10 Epoetin dose (end of treatment)." data-id="CD009904-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W), Outcome 10 Epoetin dose (end of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 CERA lower versus higher doses, Outcome 1 All‐cause mortality." data-id="CD009904-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 CERA lower versus higher doses, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 CERA lower versus higher doses, Outcome 2 Hypertension." data-id="CD009904-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 CERA lower versus higher doses, Outcome 2 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 CERA lower versus higher doses, Outcome 3 Blood transfusion." data-id="CD009904-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 CERA lower versus higher doses, Outcome 3 Blood transfusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 CERA lower versus higher doses, Outcome 4 Haemoglobin (change during treatment)." data-id="CD009904-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 CERA lower versus higher doses, Outcome 4 Haemoglobin (change during treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 CERA lower versus higher doses, Outcome 5 Need for one or more dose decrease." data-id="CD009904-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 CERA lower versus higher doses, Outcome 5 Need for one or more dose decrease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 CERA lower versus higher doses, Outcome 6 Need for one or more dose increase." data-id="CD009904-fig-0052" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 CERA lower versus higher doses, Outcome 6 Need for one or more dose increase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 CERA lower versus higher doses, Outcome 7 Achieved haemoglobin level target." data-id="CD009904-fig-0053" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 CERA lower versus higher doses, Outcome 7 Achieved haemoglobin level target. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 CERA versus placebo, Outcome 1 Major adverse cardiovascular event." data-id="CD009904-fig-0054" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 CERA versus placebo, Outcome 1 Major adverse cardiovascular event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 CERA versus placebo, Outcome 2 Cancer." data-id="CD009904-fig-0055" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 CERA versus placebo, Outcome 2 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 CERA versus placebo, Outcome 3 Hypertension." data-id="CD009904-fig-0056" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 CERA versus placebo, Outcome 3 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 CERA versus placebo, Outcome 4 Hyperkalaemia." data-id="CD009904-fig-0057" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 CERA versus placebo, Outcome 4 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009904-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/urn:x-wiley:14651858:media:CD009904:CD009904-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_t/tCD009904-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 CERA versus placebo, Outcome 5 End of treatment eGFR [mL/min/1.73 m²]." data-id="CD009904-fig-0058" src="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 CERA versus placebo, Outcome 5 End of treatment eGFR [mL/min/1.73 m²].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/media/CDSR/CD009904/image_n/nCD009904-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009904-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CERA for the anaemia of CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> CKD patients (any stage) treated for anaemia </p> <p><b>Intervention:</b> CERA </p> <p><b>Comparison:</b> epoetin alfa or beta, darbepoetin alfa, differing strategies for administration (higher versus lower doses; longer versus shorter dosing intervals) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b> Comparison</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> <p><b>per 100 patients treated for 12 months</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments<sup>#</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more (2 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.73 to 1.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1846 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more (2 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.75 to 1.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1657 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA Q2W</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more (3 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.56 to 1.66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA lower dose</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.95 (0.17 to 91.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>One or more red cell transfusions</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (3 fewer to 5 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.72 to 1.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1824 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer<br/> (5 fewer to 7 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.55 to 1.61)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1728 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> <p>Inconsistency ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA Q2W</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer<br/> (5 fewer to 7 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.51 to 1.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA lower dose</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 more<br/> (3 fewer to 519 more) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.16 (0.89 to 19.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> <p>Inconsistency ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vascular access thrombosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more (6 fewer to 15 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (0.49 to 2.40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1419 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> <p>Inconsistency ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA Q2W</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer (4 fewer to 4 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.61 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA lower dose</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Epoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more (5 fewer to 7 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.75 to 1.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1821 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Darbepoetin</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more (4 fewer to 5 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.79 to 1.28)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1752 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA Q2W</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA Q4W</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer (5 fewer to 3 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.60 to 1.21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CERA lower dose</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CERA higher dose</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 fewer (50 fewer to 82 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45 (0.08 to 2.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CERA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>PLACEBO</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 fewer (4 fewer to 4 more)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.37 to 1.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>235 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study limitation ⊝</p> <p>Imprecision ⊝</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; Q2W<b>:</b> once every 2 weeks administration; Q4W<b>:</b> once every 4 weeks administration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><sup>#</sup>We did not downgrade for reason of publication bias as insufficient studies contributed to treatment estimates to draw meaningful conclusions </p> <p>GRADE Working Group grades of evidence</p> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CERA ‐ continuous erythropoiesis receptor activator</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009904-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Health‐related quality of life outcomes in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Stage of CKD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Tool</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CERA versus epoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0002" title="ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA‐PO212]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644218] KlingerM , AriasM , VargemezisV , BesarabA , SulowiczW , GerntholtzT , et al. Efficacy of intravenous methoxy polyethylene glycol‐epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases2007;50(6):989‐1000. [MEDLINE: 18037099] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] ">AMICUS Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> <p>(HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐form 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinically meaningful changes from baseline (≥ 5 points) to week 13 and week 25 were noted in patients treated with CERA (score changes were reported in figure) </p> <p><b>Comparative effects for CERA versus epoetin on HRQOL were not reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> <p>(HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Korean version of Short‐form 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 13, a meaningful decrease (≥ 5 points) was observed on physical functioning for CERA group. At week 25, mean scores increased on all sub‐scales except role‐emotional for CERA group and clinically meaningful improvements was observed in vitality for CERA group (score changes were reported in figure) </p> <p><b>Comparative effects for CERA versus darbepoetin alfa on HRQOL were not reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CERA versus darbepoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐form 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to baseline, mean scores increased on each of the eight sub scales and summary scores in both treatment groups, representing an improvement in each parameter (score changes were reported in figure). Clinically meaningful improvements from baseline to weeks 13 and 29 (≥ 5 points) were observed for CERA once every 2 week in general health, vitality, role emotional, role physical (week 13 only), and social functioning and for darbepoetin alfa in vitality, role emotional, and role physical </p> <p><b>Comparative effects for CERA versus darbepoetin alfa on HRQOL were not reported</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CERA ‐ continuous erythropoiesis receptor activator; CKD ‐ chronic kidney disease; HD ‐ haemodialysis; HRQOL ‐ Health‐related quality of life; PD peritoneal dialysis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Health‐related quality of life outcomes in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009904-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects reported in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Stage of CKD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA versus epoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse events during the study were mild to moderate, among which thrombosed arteriovenous shunt was considered as the most specific complication to the given medications, nevertheless incidence remained low </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0007" title="ChenN , QianJQ , MeiCL , ZhangAH , XingCY , WangL , et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi‐center trial. Chung‐Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2012;51(7):502‐7. [MEDLINE: 22943819] ">Chen 2012e</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events did not differ between groups (P &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0013" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , BernardoM , LocatelliF , delAguilaM , EdwardesM , BexonM . Once‐monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SU‐PO779]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):756A. [CENTRAL: CN‐00757405] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LevinNW , MannJF , LewisJL , BernardoM , LundeNM , et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO205]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00757097] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LevinNW , FishbaneS , CanedoFV , ZeigS , NassarGM , MoranJE , et al. Intravenous methoxy polyethylene glycol‐epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non‐inferiority trial (MAXIMA).[Erratum appears in Lancet. 2008 Feb 2;371(9610):386]. Lancet2007;370(9596):1415‐21. [MEDLINE: 17950856] LevinNW , FishbaneS , ZeigS , NassarG , MoranJ , VillaG , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SO023]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv11. [CENTRAL: CN‐00757059] LevinNW , ImbasciatiE , CombeC , RoccoMV , LokCE , DonnellySM , et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA‐PO206]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00755210] MannJ , LocatelliF , SulowiczW , NissensonA , PortolesJ , LevinN , et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00791257] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. NissensonA , NassarG , EdwardesM , BeswickR , BernsJ . C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F‐PO855]. Journal of the American Society of Nephrology2007;18(Abstracts):290A‐1A. RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] ">MAXIMA Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events did not differ between groups (P = 0.12).The most common serious adverse events were sepsis, pneumonia and arteriovenous graft thrombosis. Only 6 patients had serious adverse events that were judged to be treatment‐related (three and two with CERA every 2 and 4 weeks, respectively, and one with epoetin; P = 0.40) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0017" title="OhJ , JooK , ChinH , ChaeDW , KimSG , ChungWK , et al. Mircera corrects anemia in Korean patients with chronic kidney disease on dialysis: Results from a randomized controlled multicenter study [abstract no: Su573]. NDT Plus2010;3(Suppl 3):iii502‐3. [EMBASE: 70484793] OhJ , JooKW , ChinHJ , ChaeDW , KimSG , KimSJ , et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long‐term hemodialysis. Journal of Korean Medical Science2014;29(1):76‐83. [MEDLINE: 24431909] ">Oh 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall and frequently reported adverse events during the correction phase were comparable between the two study arms. Serious adverse events were reported 14 events in 10 patients (26.3%) in CERA and 7 events in 6 patients (15.4%) in epoetin beta group. None of them was judged to be related with study drugs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0021" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi351. [CENTRAL: CN‐00757500] ChanuP , GieschkeR , ReignerB , DoughertyFC . Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once‐monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi342. [CENTRAL: CN‐00757502] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] FishbaneS , LiuS , BeswickR , NissensonA . C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled phase III analysis [abstract no: F‐PO834]. Journal of the American Society of Nephrology2007;18(Abstracts):285A. ImbasciatiE , BernardoM , CaramanP , David‐NetoE , HarrisK , LawA , et al. Stable haemoglobin (Hb) levels are maintained with once‐monthly C.E.R.A. in dialysis patients with varying C‐reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00758076] LocatelliF , SulowiczW , HarrisK , SelgasR , KaufmanJ , KlingerM , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1‐3 times per week in patients with CKD on dialysis [abstract no: SA‐PO207]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00626009] NissensonA , KwokA , BeswickR , FishbaneS . C.E.R.A. once monthly maintains stable Hb levels in patients with CKD on dialysis with and without congestive heart failure (CHF) [abstract no: 58]. American Journal of Kidney Diseases2007;49(4):A39. RyckelynckJP , HarrisK , SelgasR , StomporT , LadanyiE , OpatrnaS , et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SA‐PO210]. Journal of the American Society of Nephrology2006;17(Abstracts):620A. [CENTRAL: CN‐00644371] RyckelynckJP , Valdes CanedoF , RiellaM , LempertK , DonnellyS , AdrogueH , et al. Once‐monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi411. [CENTRAL: CN‐00644372] SulowiczW , LocatelliF , BallaJ , CsikyB , RikkerC , AldigierJ , et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv156‐7. [CENTRAL: CN‐00601914] SulowiczW , LocatelliF , RyckelynckJP , BallaJ , CsikyB , HarrisK , et al. Once‐monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology: CJASN2007;2(4):637‐46. [MEDLINE: 17699476] ">PROTOS Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD, PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events were hypertension, procedural hypotension (induced by dialysis), nasopharyngitis, headache, and diarrhoea. Most events were mild or moderate in intensity and distributed evenly across groups. The incidence of treatment‐related adverse events was low in all groups (once monthly CERA 6%; twice monthly CERA 4%; epoetin 2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] SpinowitzB , CoyneDW , FraticelliM , AzerM , DalalS , VillaG , et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre‐filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology2006;17(Abstracts):895A. [CENTRAL: CN‐00653773] SpinowitzB , CoyneDW , LokCE , FraticelliM , AzerM , DalalS , et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology2008;28(2):280‐9. [MEDLINE: 18004064] ">RUBRA Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (PD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The overall incidence of adverse events was similar between the two treatment groups; at least one adverse event was experienced by 94.5% and 94.6% of patients in the CERA and epoetin groups, respectively. Most events were mild to moderate in intensity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA versus darbepoetin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0001" title="Al‐AliFS , El‐SayedAM , FawzyAA , HamdyAF , AbdullaAE . Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodialysis International2015;19(1):33‐43. [MEDLINE: 24894344] ">Al‐Ali 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall adverse events during the study were mild to moderate, among which thrombosed arteriovenous shunt was considered as the most specific complication to the given medications, nevertheless incidence remained low </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0003" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of patients who experienced one or more adverse events was similar between groups and typical of this patient population. The most commonly reported adverse events included hypertension, peripheral oedema, diarrhoea, and nasopharyngitis. Most events were mild or moderate and very few were considered treatment related (CERA 7.5%; darbepoetin alfa 5.6%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0008" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most adverse events experienced by patients in each study arm were reported to be mild to moderate intensity, and rates were comparable between the two groups. The most frequently reported adverse events were hypertension, renal impairment, hyperkalaemia, upper respiratory tract infection and constipation. Numerically more patients in the darbepoetin alfa arm experienced resinous adverse events compared with patients in the CERA arm (12% versus 6% respectively). No patient had a serious adverse event that was judged to be treatment related </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0019" title="BesarabA , CanaudB , deFranciscoALM , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] CarreraF . C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events did not differ between groups (P = 0.55). Six were judged to be related to treatment (four with CERA and two with darbepoetin alfa, respectively). Serious adverse events were comparable in the two groups (P = 0.71). The most common serious adverse events were arteriovenous fistula site complication, arteriovenous fistula thrombosis and sepsis. No patient had serious adverse events that was judged to be treatment related </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0024" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The overall incidences of adverse and serious adverse events were similar between the two treatment groups and typical of the patient population. The most commonly reported adverse events were diarrhoea, nasopharyngitis and influenza. Serious adverse events were considered to be related to study treatment in one patient in the CERA group (arteriovenous graft thrombosis) and three patients in the darbepoetin group (arteriovenous graft thrombosis, arteriovenous fistula site haemorrhage and cerebral infarction) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA lower versus higher doses</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0004" title="DoughertyFC , ReignerB , BeyerU . Dose‐dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in multiple‐dose study of dialysis patients with chronic renal anaemia [abstract no: MP280]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:325. [CENTRAL: CN‐00509162] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] deFranciscoAL , SulowiczW , DoughertyFC . Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple‐dose study [abstract no: SA‐FC124]. Journal of the American Society of Nephrology2003;14(Nov):27A‐8A. [CENTRAL: CN‐00550366] deFranciscoAL , SulowiczW , KlingerM , NiemczykS , VargemezisV , MetivierF , et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study.[Erratum appears in Int J Clin Pract. 2007 Oct;61(10):1776‐7]. International Journal of Clinical Practice2006;60(12):1687‐96. [MEDLINE: 17109676] ">BA16260 Study 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events were gastrointestinal disorders, infections, nervous system and vascular disorders. Most events were mild or moderate in intensity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0012" title="KinugasaE , YumitaS , SatoT , KurosawaA , KitaokaT , SugimotoH , et al. A dose‐finding study of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in renal anemia patients on hemodialysis ‐ A randomized double‐blind comparative study. Japanese Pharmacology &amp; Therapeutics2011;39(Suppl 1):S9‐S19. [EMBASE: 2011317486] ">Kinugasa 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (HD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The adverse events manifested were similar among the dose groups investigated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0022" title="BesarabA , ProvenzanoR , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Dose‐dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi‐dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO930]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747325] ProvenzanoR , BesarabA , MacdougallIC , DoughertyFC , BeyerU . CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. [abstract no: SU‐PO056]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00747313] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis [abstract no: SA‐PO929]. Journal of the American Society of Nephrology2005;16:760A. [CENTRAL: CN‐00747324] ProvenzanoR , BesarabA , MacdougallIC , EllisonDH , MaxwellAP , SulowiczW , et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clinical Nephrology2007;67(5):306‐17. [MEDLINE: 17542340] ProvenzanoR , DoughertyFC . Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis [abstract no: 126]. American Journal of Kidney Diseases2006;47(4):A50. [CENTRAL: CN‐00747315] ">Provenzano 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events were hypertension, urinary tract infection and kidney failure. The majority of events were mild or moderate in intensity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b> CERA versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009904-bbs2-0020" title="FliserD , DellannaF , KochM , SeufertJ , WitzkeO , HauserIA . The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non‐anemic patients with chronic kidney disease. Contemporary Clinical Trials2011;32(6):786‐92. [MEDLINE: 21762788] FliserD , DellannaF , KochM , WiggenhauserA , PRIMAVERA Study Group. Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial. Nephrology Dialysis Transplantation2017;32(2):279‐87. [MEDLINE: 28186540] ">PRIMAVERA Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events with a suspected relation to the study drug occurred in 22% and 16% of patients randomised to CERA and placebo, respectively </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CERA ‐ continuous erythropoiesis receptor activator; CKD ‐ chronic kidney diease; HD ‐ haemodialysis; PD ‐ peritoneal dialysis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects reported in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/full#CD009904-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009904-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CERA versus epoetin alfa or beta</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.73, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major adverse cardiovascular event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Vascular access thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.49, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.18, 3.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1821</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.72, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Iron supplementation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.91, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Haemoglobin (end of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.34, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Haemoglobin (change during treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.04, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Achieved haemoglobin level target <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Exceeding haemoglobin level target <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Epoetin dose (end of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.11 [‐3.60, ‐0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 One or more hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serum ferritin at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.43, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Transferrin saturation at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CERA versus epoetin alfa or beta</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009904-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CERA versus darbepoetin alfa</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.75, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.74, 3.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major adverse cardiovascular event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.56 [0.99, 31.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.63, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Achieved haemoglobin level target <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.93, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Haemoglobin (end of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.13, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Haemoglobin (change during treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.05, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Epoetin dose (end of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.30, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Exceeding haemoglobin level target <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Time within the target haemoglobin range <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Need for one or more dose increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Need for one or more dose decrease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.55, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Iron supplementation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.95, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serum ferritin at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.31, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Transferrin saturation at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [‐1.39, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CERA versus darbepoetin alfa</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009904-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.56, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Vascular access thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.61, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.60, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Haemoglobin (end of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.00, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Haemoglobin (change during treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.12, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Achieved haemoglobin level target <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.36, 134.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.51, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Epoetin dose (end of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.20 [‐35.52, 13.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CERA: once every 2 weeks (Q2W) versus once every 4 weeks (Q4W)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009904-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">CERA lower versus higher doses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.08, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [0.89, 19.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Haemoglobin (change during treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.26 [‐1.77, ‐0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for one or more dose decrease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Need for one or more dose increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [0.89, 19.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Achieved haemoglobin level target <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">CERA lower versus higher doses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009904-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">CERA versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Major adverse cardiovascular event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 End of treatment eGFR [mL/min/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">CERA versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009904.pub2/references#CD009904-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009904.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009904-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009904-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD009904-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009904-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009904\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009904\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009904\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009904\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009904\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009904.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009904.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009904.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009904.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009904.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728798923"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009904.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728798927"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009904.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecd486984f56f',t:'MTc0MDcyODc5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 